Abstract
Intensive food animal production is at risk due to the ever-increasing antimicrobial resistance (AMR) of veterinary pathogens, and it is time to look at alternatives to antibiotics. Bacteriophage (phage) cocktails, which involve the use of several bacteriophages with different host ranges and resistance profiles, are a new and exciting biologic approach. Nevertheless, there are significant physicochemical barriers in the animal host and during feed processing that hinder the translation of promising in vitro bacteriolysis to consistent in vivo therapeutic efficacy. The review critically addresses the interrelated issues of gastric acidity, enzymatic digestion, exposure to bile salts, thermal stress during feed pelleting and osmotic fluctuations, which all contribute to the destruction of orally administered phage titers. We systematically examine formulation technologies such as lyophilization, spray-drying, and alginate, chitosan, lipid nanoparticles and hydrogel encapsulation to protect phages from these destructive environments. When comparing the delivery routes of oral, parenteral, intramammary and aerosol, it is observed that each route places different priorities on biopharmaceutical requirements. Critical evaluation of therapeutic outcomes in poultry, swine, ruminants, and aquaculture has shown that the use of formulations optimized for the gastrointestinal physiology of the target species can lead to significantly reduced target bacterial loads and mortality rates, but failures often occur when in vitro stability data is not supported by an understanding of the pharmacokinetic parameters. For ruminants, there is a remarkable difference between the success of acid-resistant encapsulation in monogastrics and the inability of such methods to work in ruminants due to premature release and inactivation of phages by the forestomach microbiome. We emphasize the need for standardized assays of phage titer in different laboratories, well-defined regulatory processes, and physiologically-based pharmacokinetic/pharmacodynamic models that can predict the temporal and spatial dynamics of phage-bacteria interactions in vivo. This synthesis provides a roadmap for the rational design of phage cocktail products that can reliably reduce antibiotic dependence in veterinary medicine.
1 Introduction
The global intensification of poultry, swine, bovine, and aquaculture production has been accompanied by a steep increase in the use of antimicrobials for metaphylaxis, growth promotion, and treatment of infectious diseases. This selective pressure has accelerated the emergence and dissemination of multidrug-resistant (MDR) zoonotic and animal-specific pathogens, including extended-spectrum β-lactamase-producing Escherichia coli, methicillin-resistant Staphylococcus aureus (MRSA) in swine and dairy cattle, fluoroquinolone-resistant Campylobacter spp. in broilers, and Vibrio spp. harboring plasmid-mediated resistance in shrimp farming (1ā3). Recognizing that antimicrobial resistance (AMR) threatens not only animal health but also human food safety and global public health, international bodies such as the WHO, OIE, and FAO have called for drastic reductions in veterinary antibiotic consumption and the development of effective alternatives (4, 5).
One of the most promising biological interventions are bacteriophages, viruses that specifically infect and lyse bacteria. Today, with the help of modern molecular biology and synthetic biology tools, the historical roots of the use of phages as therapy are revived as laid by dāHerelle in the early 20th century (6). Food-animal medicine presents a number of intrinsic advantages for the use of phages: they multiply in the area of infection, they are not harmful to mammalian cells, they can break down biofilms, and they are highly host-specific, which means that they have minimal impact on commensal flora (7). In most cases, however, monophage preparations will result in the rapid emergence of phage-resistant bacterial mutants, as observed in the models of Salmonella, Campylobacter, E. coli and Aeromonas (8, 9). Phage cocktails, which consist of a combination of several phages targeting different receptors or using different infection strategies, significantly lower the chances of the development of phage resistance and expand the range of host strains of circulating field strains (10). Thus, regulatory talks and commercial development projects are shifting to more well-defined cocktails instead of individual products per phage (11).
Although there is a lot of in vitro data showing that the cocktails are very effective at killing bacteria, the clinical effectiveness of the oral application of the cocktails in production animals is inconsistent (12). This is because phages are proteinaceous nanoparticles which are highly susceptible to the harsh physicochemical conditions that exist during storage, feed processing and gastrointestinal transit. The number of viable phages can drop by several orders of magnitude within minutes due to gastric acidity (pHāÆ<āÆ3), pepsin-mediated proteolysis, pancreatic trypsin, a high temperature during pelleting (70ā90āÆĀ°C) and osmotic shocks in the drinking water delivery system (13, 14). Furthermore, the prandial state of the animal, digestive physiology and the dosage form have a significant impact on the proportion of the dose that reaches the target site in an active form (12). The main argument of this review is that to close the in vitroāin vivo gap in therapeutic efficacy in the treatment of bacterial infections requires a systematic approach that combines the biology of phages with the science of pharmaceutical formulation and species-specific pharmacokinetics.
The following sections present a comprehensive, critical analysis of: (i) physicochemical barriers to phages in vivo and ex vivo; (ii) formulation technologies designed to overcome these barriers; (iii) the effects of the delivery route on the formulation requirements; (iv) therapeutic outcomes in poultry, swine, ruminants, and aquaculture, focusing on the correlation of formulation characteristics and clinical endpoints; and (v) what remains to be done in scale-up, regulation, resistance management, and assay standardization. The entire pipeline for development of a bacteriophage cocktail is plotted in Figure 1 from the isolation of the phages to their application in the field, in eight sequential steps discussed throughout this review. Differences between high in vitro stability and in vivo success are emphasized throughout and the reasons for the failure of some encapsulation methods in the ruminant forestomach are explained.
Figure 1
2 Physicochemical hurdles to phage cocktail viability in vivo and ex vivo
2.1 Gastric acidity and pH gradients
The first big challenge to phages that are given orally is the low pH in the stomach. Gastric pH is as low as 1.5ā2.5 in fasted pigs and poultry (15) and 4.0ā5.0 in fed animals, due to the buffering effect of feed (16, 17). Structural proteins of phages, including tail fibers and capsid subunits, are irreversibly denatured and aggregated at pH levels below 3.0, resulting in a rapid decrease in infectivity (18). The effect of exposure to simulated gastric fluid (SGF) (pH 2.5) for 30- to 60-min periods has been shown to decrease the number of Salmonella phages by 4ā7 log10 PFU/mL (19). The stability of five coliphages (four of the family Myoviridae and one of the family Siphoviridae) was evaluated and it was found that the Myoviridae phages were stable in a pH range between 2.0 and 7.0, while the Siphoviridae phage (JK16) was highly sensitive to low pH conditions (20). There is known significant interspecies and interstrain variation in acid tolerance. For instance, S. aureus phages were found to be stable over the pH range 3.0 to 11.0 (21) and were completely inactivated at pH 3.0 after 24āÆh (22) with partial inactivation observed at intermediate pH levels. The receptor-binding protein structure and the presence of phase-variable modifications of the capsular polysaccharide (e.g., O-methyl phosphoramidate (MeOPN)) are critical phage receptors in Campylobacter phages and known to strongly influence survival and host range (23, 24). This variability highlights the importance of characterizing the acid sensitivity of each phage in a cocktail separately prior to the formulation design.
The pH gradient from the stomach to the small intestine is not a discrete step but a dynamic continuum. The pH in the duodenum quickly increases to 6.0ā6.5 because of the secretion of bicarbonate, which can renature some phages if the denaturation was not followed by proteolytic cleavage (25). In an in vitro gastrointestinal model (TIM-1), phages were shown to be able to survive the acidic stomach environment and be delivered to the ileal compartment, with up to 27% of the initial phage dose recovered in the ileal compartment when suspended in a protective matrix like milk concentrate (26). A fraction of the dose can thus be saved using formulation strategies that will delay the release of the phages until the pH is above 5.5.
2.2 Enzymatic degradation (pepsin, trypsin, pancreatic enzymes)
Proteolytic enzymes in the stomach (pepsin) and small intestine (trypsin, chymotrypsin, elastase) are a major problem for phage proteins (27). Pepsin, whose optimum pH is 2, can break exposed peptide bonds and can rapidly break down the capsid and tail proteins of phages, even at low levels of acid-induced denaturation (28). In vitro experiments with simulated intestinal fluid (SIF) containing trypsin have shown that many E. coli and Salmonella phages lose 3ā5 log10 of viability within 1ā2āÆh (14, 29). The effect of pepsin on the viability of phages has been reported: Dini et al. (30) showed that phages encapsulated in alginate were protected from proteolytic degradation when challenged with simulated gastric conditions (pH 2.5, 3.2āÆmg/mL pepsin). Non-encapsulated phages, on the other hand, are completely inactivated in 10āÆmin at pH 1.6 and with pepsin concentrations as low as 0.5āÆmg/mL (30). The enzyme may be encapsulated within a polymeric matrix, which may sterically hinder the approach of the enzyme to the phage surface, and the size of the pores in hydrogels is usually in the range of 5ā200āÆnm, depending on the degree of crosslinking (31). The polymers, excipients, and crosslinking agents used have an impact on the protection of phages from gastric acid and digestive enzymes (32).
2.3 Bile salts and surfactant effects
In the fed animal, the bile salts secreted into the duodenum can reach concentrations of up to 20āÆmM, and are amphipathic molecules that can disrupt lipid membranes and denature proteins. With a few exceptions, including some species in the Corticoviridae (33, 34), phages are not covered with a lipid envelope, but bile salts can still have a profound effect on the viability of phages. For instance, free bacteriophage Felix O1 reduced by 1.29 and 1.67 log units after 3āÆh in 1 and 2% bile solutions, respectively (35). The scanning electron microscope revealed a significant degree of aggregation of the phages and tail sheath contraction, which is irreversible structural damage (36). Interestingly, phages with a higher surface charge or hydrophilicity (PEGylation), exhibit enhanced resistance to bile inactivation (37). Surface plasmon resonance (SPR) experiments showed that the binding affinity of PEGylated phages to bile acid micelles was 10-fold lower than that of native phages (37, 38). This observation has prompted interest in surface-modified phages or bile-salt-sequestering excipients for oral formulations. At the same time, dietary fibers like β-glucan are known to bind bile salts in the intestinal lumen (39, 40). This property is well known for cholesterol-lowering properties, but the ability of this property to protect the co-administered phages from inactivation by bile needs to be studied. Nevertheless, β-glucan has been proven to be a biocompatible matrix for the formulation of phages and their viability is maintained at >99% during storage (41).
2.4 Mucosal trapping and immune clearance
In addition to chemical degradation, phages are faced with physical obstacles like the mucus layer and the innate immune system of the host. Intestinal mucus, which consists of mucin glycoproteins, can trap phage particles by adhesive interactions, which will decrease the number of phages reaching the intestinal surface and, in turn, the intestinal lumen (42). This āmucosal entrapmentā is especially important for non-motile phages that are passive diffusers. Notably, certain phages display Ig-like domains that promote adherence to mucin, a phenomenon proposed as a non-host-derived antimicrobial defense mechanism (43). However, for therapeutic phages, this binding can lead to a decrease in the effective concentration in the lumen. Recently, a porcine intestinal organoid model revealed that mucus-associated phages were removed from the intestinal lumen at 3ā5 times the rate of non-mucoadhesive phages, which reduced the availability of subjacent intestinal pathogens (44). To counteract this, phage display engineering has been investigated to weaken mucin-binding whilst retaining the ability to bind to the receptor of the target bacteria.
Phages injected into the body are rapidly eliminated by the mononuclear phagocyte system, mainly in the liver and spleen. The liver has been found to contain 70ā90% of the phages, and it is the Kupffer cells that quickly inactivate the phages; the spleen was found to contain the highest titres of phages and to contain active phages for the longest time (45, 46). This fast clearance requires high initial titres or repeated doses in systemic infections.
Additional challenges are repeated intravenous dosing. Tan et al. (47) showed that repeated IV phage administration in rats and monkeys led to a 2ā3 log10 reduction in plasma phage titer 5āÆmin after the dose, and to splenic enlargement and the induction of phage-specific neutralizing antibodies. Immune response is route dependent, the highest and most lasting antibody response was obtained after intraperitoneal administration, and the subcutaneous administration produced weaker and delayed antibody response (48).
PEGylation has been extensively explored as a strategy to prolong phage circulation in the body (49). Recent studies have demonstrated that the attachment of 5āÆkDa PEG chains to phage capsids can modify more than 60% of the surface without impairing replication competence. PEG-modified phages are more stable in blood serum, persist longer within the macrophages and remain in circulation longer in healthy and infected mice. Also, these PEGylated phages cause much lower levels of anti-phage antibodies compared to normal phages and help reduce harmful inflammation markers like IL-6, TNF-α, IFN-γ, and IL-1β to normal levels. However, other techniques, such as the use of poly(2-oxazoline) or zwitterionic coatings should be considered due to the possibility of developing antibody against PEG in some individuals (49).
2.5 Temperature fluctuations during feed pelleting and storage
For poultry and swine, steam conditioning and pelleting are standard methods for processing feed, typically between 70ā90āÆĀ°C. The majority of tailed phages (order Caudovirales) are extremely temperature sensitive, and high temperatures during processing are a significant formulation challenge (50). This significant heat sensitivity is a significant challenge for using phage cocktails in pelleted feeds unless protective formulations are used. Phages can become inactive over time in liquid feed or drinking water systems at farm ambient temperatures. The viability of lyophilized phage powders stored at 4āÆĀ°C is generally months, and Manohar and Ramesh (51) showed the viability of phage cocktails at 4āÆĀ°C and 37āÆĀ°C to be months and 10āÆmonths, respectively, when lyophilized with sucrose-gelatin excipients. However, in resource-limited farming environments, cold-chain logistics remain a major challenge (52).
2.6 Osmotic and ionic strength variations in water and buffers
Phage stability is highly dependent on the ionic environment. The ionic environment plays a very critical role in phage stability. Some phages need divalent cations (Ca2+, Mg2+) to adsorb and inject their genome into the bacteria, and hypotonic shock can lead to the disruption of the capsid. Leibo and Mazur (53) showed that bacteriophages T4B and T4D undergo osmotic shock and are very sensitive to low monovalent salt concentrations, but there is strain-specific variation in sensitivity. Almost half of the osmotically shocked phages had their DNA intact, but they were no longer infective, suggesting that the phages suffered from structural damage (53).
The hardness and salinity of the drinking water provided to farms is variable and can cause osmotic lysis in the case of ultrapure water, and aggregation and loss of infectivity in the case of high salinity. Phages should be stabilized with standard laboratory buffers, such as SM buffer (100āÆmM NaCl, 10āÆmM MgSO4, 50āÆmM TrisāHCl, pH 7.5, 0.01% gelatin). It has been demonstrated that SM buffer at 4āÆĀ°C can keep the infectivity of phages for up to 30āÆdays and DNA for up to 100āÆdays (54). However, such buffers are not economically viable for water medication systems of large scale.
Other excipients such as trehalose and skim milk powder also act to buffer against osmotic stress and are essential for the development of drinking waterāstable formulations. Xu et al. (55) showed that skim milk powder along with trehalose reduced the extent of phage inactivation during lyophilization and subsequent storage at 28āÆĀ°C. Kim et al. (56) prepared a stabilizing solution using sugars and salts, which greatly enhanced the survival of the phages in distilled water. Skim milk powder probably forms a protective protein corona around the phage particles, which is why it is able to preserve the titer even in water with low ionic strength.
2.7 Impact of prandial state (fed vs. fasted)
Gastric residence time, pH and enzyme secretion are significantly altered in the prandial state. In fasted animals, the pH of the stomach may reach 1.5ā3.5, which is a very harsh environment for phages to survive in (57). On the other hand, the food matrix may protect the phages from the gastric acidity and act as physical protection during gastric transit. In dynamic gastrointestinal models, the protective effect of food matrices has been shown. Samtlebe et al. (26) used TIM-1 to show that a lactococcal phage P008 was able to survive in high numbers (>90%) after passing through the upper human gastrointestinal tract, and that high numbers of phages were delivered from the ileal compartment after 4āÆh of digestion. Interestingly, by delivering up to 27% in the ileal compartment, phages in milk concentrate appeared to be protected by the dairy matrix (26).
The significance of protective formulations for oral phage delivery has been confirmed by other studies. Phages were encapsulated in alginate with milk proteins, which protected phages from the acidic conditions (pH 2.5) for 2āÆh, and released in 30āÆmin in intestinal conditions (58). Likewise, VerthĆ© et al. (59) showed that at the gastric pH of 2.0, phage UZ1 was completely inactivated, whereas no significant changes in phage titer were seen after 2āÆh incubation at 37āÆĀ°C if an antacid was used to neutralize the stomach acidity.
Smith et al. (60) had direct evidence that the interaction of prandial state, feed composition and phage survival occurred in calves. Phages were found in the small intestine at high levels (6.5ā6.8 log PFU/g contents) and in the abomasum (pH 4.4) 0.3āÆh after phages were administered in milk to fasted calves. However, by 5āÆh after feeding (when the pH in the abomasum was 1.8), there was a significant reduction in phage titers; some phages were not detectable in the abomasum and lower titers in the small intestine. Phage survival during gastrointestinal transit was improved and gastric pH was maintained by the addition of CaCO3 to milk (60).
The interplay between formulation, meal timing, and gastric physiology must be empirically defined for each target species, since the gastric physiology of fed and fasted animals and across species will differ. From these results, it is recommended that oral phage cocktails be used in protective food matrices or with the use of encapsulation techniques that will protect the phages from the acidic environment of the stomach. The above physicochemical barriers, the basic mechanism of phage action and strategies to overcome resistance are summarized in Figure 2. The key physicochemical barriers to phage viability in the gastrointestinal tract, along with their corresponding mitigation strategies, are summarized in Table 1.
Figure 2
Table 1
| Barrier | Relevant site(s) | Effect on phages | Formulation mitigation strategy | Key references |
|---|---|---|---|---|
| Gastric acidity (pH 1.5ā2.5 fasted) | Stomach (monogastrics), abomasum (ruminants) | 4ā7 log10 loss in 30ā60āÆmin; capsid denaturation, tail fiber unfolding | Enteric coatings (EudragitĀ®), alginateāchitosan encapsulation, fed-state administration, milk-based buffers | (19, 20, 57) |
| Pepsin (pH 1.5ā2.5) | Stomach | Synergistic with acid; cleaves capsid and tail proteins; non-encapsulated phages inactivated at 0.5āÆmg/mL pepsin within 10āÆmin | Dense hydrogel matrices (pore size 5ā200āÆnm), alginate encapsulation, Ca2+-stabilized capsules | (27, 30, 31) |
| Bile salts (ā¤20āÆmM) | Duodenum | 1.29ā1.67 log10 loss in 3āÆh (1ā2% bile); capsid hydrophobic patch binding, aggregation, tail sheath contraction | PEGylation, hydrophilic surface coatings, alginateāchitosan encapsulation, β-glucan as bile-salt adsorbent | 35ā37 |
| Trypsin/Chymotrypsin | Small intestine | 3ā5 log10 loss in 1ā2āÆh in SIF; proteolytic degradation of capsid proteins | Encapsulation with enzyme-impermeable matrices, alginateāchitosan beads, PEGylation | (29, 31) |
| Temperature (pelleting: 70ā90āÆĀ°C) | Feed mill | >5 log10 loss in 2āÆmin at 70āÆĀ°C for most Caudovirales; capsid proteins denature at 55ā60āÆĀ°C | Spray-dried microcapsules with high-Tg excipients (trehalose, whey protein), isolation of thermostable phages, cold pelleting | (50, 71) |
| Osmotic/ionic stress (drinking water) | Farm water lines | Hypotonic shock causes capsid rupture; low-mineral water (<50āÆppm TDS) causes titer loss; high salinity (>1% NaCl) promotes aggregation | Addition of SM buffer salts (MgSO4, NaCl), skim milk powder (2ā5%), trehalose, sugar/salt stabilizing solutions | (53, 54, 56) |
| Mucosal trapping | Intestine, lung | Reduced luminal phage concentration; mucus-associated phages cleared 3ā5āÆĆāÆfaster than non-mucoadhesive phages | Engineering of tail fibers to reduce mucus binding; selection of non-mucoadhesive phage variants | (42ā44) |
| Residual chlorine (0.5ā2.0āÆppm) | Drinking water | 1ā3 log10 inactivation within 30āÆmin | Sodium thiosulfate, skim milk powder to quench chlorine; sugar/salt stabilizing solutions | (56) |
| Mononuclear phagocyte system (MPS) clearance | Liver, spleen | 70ā90% of phage particles concentrate in liver; plasma half-life of minutes in large animals; 2ā3 log10 decline upon repeated IV dosing | PEGylation (>60% surface modification), serial-passage (long-circulating mutants), liposome encapsulation | (45ā47, 49) |
| Antibody-mediated neutralization | Systemic circulation | Free phages neutralized within 3āÆh of antibody interaction; 38.5% immune neutralization in patients | Liposome encapsulation (100% protection), PEGylation (lower anti-phage IgG), intranasal delivery (avoids systemic antibodies) | (76, 84, 90, 145) |
Physicochemical barriers to phage viability in the gastrointestinal tract and mitigation strategies.
3 Formulation strategies for enhancing phage stability
3.1 Liquid and lyophilized bulk formulations (excipients and buffers)
Liquid formulations stabilized with buffer salts, sugars and proteins are the simplest phage formulations. Phage can survive in tris-buffered saline containing appropriate stabilizers but this suspension provides little protection against gastric acidity or heat stress. It has been reported that the presence of SM buffer (Tris/NaCl/MgSO4) can greatly enhance the survival of phages during the dehydration process (61). Phage T7 in SM buffer formulation also exhibited a low level of loss of titer of 0.19 log PFU during thin film freeze-drying, suggesting good preservation of phage function (61).
For long-term storage, lyophilization (freeze-drying) in the presence of cryoprotectants like trehalose, sucrose, skim milk and mannitol is now the standard method. Trehalose is particularly known to form an amorphous glass that protects the phage particles from denaturation by replacing water molecules through hydrogen-bonding (62, 63). Manohar and Ramesh (51) also found that sucrose, gelatin and their mixture were beneficial in retaining the viability of the phage cocktails after lyophilization and that the viability of the cocktails was retained for up to 10āÆmonths during storage at 4āÆĀ°C.
But lyophilized cakes are hygroscopic and require to be packaged with desiccants and the reconstitution process may not be feasible in large-scale feed mills. Furthermore, lyophilization does not provide gastric acid protection and the lyophilized product must be further coated for oral delivery.
3.2 Encapsulation and micro/nano-particulate systems
3.2.1 Alginate and chitosan-based systems
Calcium alginate hydrogels are among the most widely investigated encapsulants for phages because of their mild gelation conditions (ionic crosslinking by Ca2+), biocompatibility, and pH-responsive swelling. Alginate-based hydrogels help keep phages safe from tough environmental conditions like low pH and enzymes breaking them down, which helps maintain their ability to infect and work effectively as therapy (64). Phage release from the hydrogels occurs through a swellingācollapseādegradation process influenced by environmental factors such as pH, allowing sustained delivery over extended periods. The gelation mechanism involves ionic cross-linking with calcium ions, forming a three-dimensional network that can be fine-tuned by adjusting the alginate concentration and cross-linking density (64).
Several studies have documented the protective effect of alginate encapsulation against gastric conditions. A systematic comparison of alginate-based encapsulation strategies reported that alginateāchitosan beads with a core/shell structure allowed E. coli phage ZCEC5 to resist acidic environments (pH 2) for 60āÆmin with only a 1 log10 reduction in embedded phage titer, while achieving complete phage release within 5āÆh under simulated intestinal fluid (SIF) conditions (65). Similarly, alginateāchitosan microspheres encapsulating E. coli phage O157: H7 showed resistance to pH 2 for 60āÆmin with a 1.5 log10 reduction, with 65% of embedded phage released after 6āÆh in SIF (65). Importantly, polycationic coatings such as chitosan and polyethyleneimine (PEI) on alginate beads significantly increased acid resistance; alginate-only beads showed a 4 log10 reduction at low pH, while alginateāPEI beads showed only a 1 log10 reduction (65).
For Salmonella phages, alginateāchitosan beads containing phage Felix O1 demonstrated near-complete phage release (1.6āÆĆāÆ107 PFU) within 5āÆh under SIF conditions, although exposure to SGF at pH 2.4 for 60āÆmin resulted in a 2.6 log10 reduction in phage titer. At pH 2, no phage titer was observed after 30āÆmin for this formulation (65). In comparison to alginate-only microspheres, Tang et al. (66) showed that alginateāwhey protein microspheres greatly increased phage survival in simulated gastric fluid; free phage was totally inactivated in minutes in SGF, whereas encapsulated phage largely retained viability after two hours of incubation.
Combination encapsulations have been demonstrated to be effective for extended in vivo phage activity. Kim et al. (67) have created PLGA/alginate-composite microspheres that allow for phage detection in tissues for up to 28āÆdays after administration, whereas non-encapsulated phages have been detected for only 3ā5āÆdays. The controlled release was blamed for reduced immune responses and thus enhanced prophylaxis.
Other polysaccharide mixtures have also been tested. Alginateācarrageenan and alginateāchitosan formulations have been proven to have efficiency in encapsulating phages and protecting them against acidic environment (68). In acidic environments, the recovery rates of phages in ALG-CG-CA were significantly higher than those in ALG-CG and unencapsulated phages, and the duration of phage activity and the protection uniformity were also significantly improved (69).
Although these are encouraging in vitro findings, in vivo efficacy will need to be considered. However, the use of chitosan has its drawbacks because conventional chitosan needs to be solubilized in acetic acid which affects the survivability of the phages (68). The fed state, gastric motility and interactions with feed components may affect the performance of encapsulated phages and in vivo testing is required under conditions that replicate the in vivo conditions of the target animal. This difference between in vitro and in vivo results highlights the need for dynamic dissolution models that mimic the fed-state gastric environment, fluid shear and intestinal peristalsis.
3.2.2 Spray-dried microcapsules and powder formulations
Spray-drying is a promising and scalable process for making phage powders which can be added to feed. The residence time is short and the cooling rate is fast which results in low degree of thermal degradation, but the outlet temperature is generally 50ā70āÆĀ°C, requiring thermoprotective carriers. The high glass transition temperature (TgāÆāāÆ115āÆĀ°C) and the formation of a rigid glassy matrix that immobilizes phage particles (70) make trehalose an excellent protective excipient during spray-drying, particularly for phages. It has been shown that trehalose is an excellent drying excipient for phages, with no measurable loss in phage titer over a variety of drying temperatures when trehalose is the sole excipient.
The application of Design of Experiments (DoE) techniques has allowed for optimization of the spray drying parameters in a systematic way. Tabare et al. (71) tested the viability of the phages of Pseudomonas aeruginosa LUZ19 (a podovirus) and 14ā1 (a myovirus) at varying inlet temperatures, spray gas flow rates and trehalose/L-isoleucine ratios. They found that inlet temperature did not affect the activity of the phages and that the flow rate of the spray gas had a positive correlation with the viability of the bacteriophages. The results showed that the impact of L-isoleucine on LUZ19 was positive, while the impact on 14ā1 was negative, indicating that the impact of excipients on phages is different (71).
In oral delivery applications, pH-responsive polymers like the EudragitĀ® derivatives have been added to spray dried formulations to protect against gastric degradation. Vinner et al. (50) showed that the viability of Salmonella Felix O1 was preserved during spray drying when the phage was formulated with trehalose and Eudragit S100, with no measurable loss in phage titer observed for the formulations with trehalose. Spray drying alone with Eudragit S100, however, led to a reduction of the phage to about 4 log10. The reduction in phage activity was at least 2 log10 when exposed to the simulated gastric fluid at pH 2 for 2āÆh, depending on the formulation, which means there is still room for optimization to achieve complete gastric protection (50).
Recently, Tabare et al. (70) developed colon targeted oral delivery systems with excipients of EudragitĀ® FS30D. The colonic-release polymer was chosen to prevent premature release of the phages in the stomach and small intestine, where the pH is lower. The optimized formulation was able to retain the activity of phage LUZ19 during spray-drying and was resistant to high acidic conditions. The stability studies indicated that the powder was stable for 6āÆmonths or more at 5āÆĀ°C.
Microencapsulation using spray-drying has also been shown to significantly improve phage stability in simulated gastrointestinal conditions. Using a spray dryer, Acar Soykut et al. (72) microencapsulated Bacillus subtilis and Salmonella phages with 1.33% (w/v) sodium alginate. The maximum titer loss was 2.29 log units for B. subtilis phages, 1.71 log units for S. enteritidis phages, and 0.60 log units for S. typhimurium phages after 2āÆhours of incubation in simulated stomach juice; free phages lost their viability even after 15āÆminutes. Similarly, microencapsulation increased phage stability in bile salt medium, with the difference between titers of microencapsulated and free phages reaching up to 3 log units after 3āÆh of incubation (72).
Suboor, (73) spray-dried a two-phage cocktail (myoviruses SPFM10 and SPFM14) targeting Salmonella using formulations containing trehalose, mannitol, leucine, and Eudragit S100. The phages demonstrated high survivability when formulations containing combinations of sugar, amino acid, and polymer were used. When administered to piglets, a decline in Salmonella colonies was observed (73).
However, feed mills operate under variable steam pressures and conditioning times; batch-to-batch variability remains a major manufacturing challenge. Furthermore, spray-dried powders often exhibit rapid phage release at gastric pH unless additional enteric coating is applied, which increases cost and complexity. The discrepancy between in vitro protection and in vivo efficacy highlights the need for dynamic dissolution models that simulate gastrointestinal conditions and the fed-state gastric milieu.
3.2.3 Lipid-based nanoparticles and liposomes
Liposomes and solid lipid nanoparticles (SLNs) offer a versatile platform for phage encapsulation, protecting phages from both acid and enzymes, and enabling surface functionalization for targeted delivery. Lipid-based nanocarriers have been shown to improve phage protection under harsh physiological conditions, enhancing stability, in-vivo retention, and targeted delivery (74).
Liposome encapsulation provides several advantages for phage therapy. It can help treat intracellular diseases like Mycobacterium TB, Listeria species, Salmonella species, and Staphylococcus species by facilitating phage access into phagocytic cells (75). For gastrointestinal infections, liposomes can address the common problem of short residence time of orally ingested phages by providing mucoadhesion. Furthermore, nanoencapsulation in liposomes can overcome poor phage stability under the acidic pH of the stomach (75).
Studies have demonstrated that liposome encapsulation enhances phage efficacy in vivo. For instance, chickens infected with Salmonella spp. that received treatment with a phage cocktail encapsulated in liposomes demonstrated enhanced effectiveness and extended protection. After 72āÆh of administration, encapsulated phages were detected in 38.1% of treated animals versus only 9.5% in animals receiving free phages (75). According to Pardo-Freire and Domingo-Calap (75), liposome encapsulation promoted adherence to the intestinal membrane and prolonged presence in the stomach. Similarly, the concentration of phage UAB_Phi20 in the stomach of mice was significantly higher when administered encapsulated, even 6āÆh after administration, with no decrease in phage titer over that time.
Liposome encapsulation can also protect phages from antibody-mediated neutralization. Singla et al. (76) demonstrated that entrapment of phage in liposomes provided 100% protection from neutralizing antibodies, while un-entrapped phages were neutralized within 3āÆh of interaction with antibody. Furthermore, while free phages were unable to enter macrophages, liposomes successfully delivered entrapped phages inside macrophages, achieving 94.6% killing of intracellular Klebsiella pneumoniae (76). Quantitative data from this study showed that liposome-entrapped phages-maintained titers of 5.18 log PFU/mL after 3āÆh in the presence of antibodies, whereas free phages were completely inactivated within the same timeframe (76). Chadha et al. (71) similarly reported that liposome-encapsulated phages were protected against neutralizing antibodies compared to free phages, with an encapsulation efficiency of 79.2āÆĀ±āÆ5.6% in phage-entrapped liposomes. The liposomal preparation protected mice from death even when treatment was delayed for 24āÆh, demonstrating the potential of liposome encapsulation to overcome pharmacological barriers to phage therapy (71).
Niosomes, non-ionic surfactant-based vesicles, have also been explored for phage delivery. A study that used transfersomes, nanostructured lipid-based carriers, as transdermal delivery vehicles to encapsulate a cocktail of methicillin-resistant Staphylococcus aureus (MRSA) phages showed more stability and persistence than free phages. Transfersome-entrapped phage cocktail-treated rats recovered from experimental thigh infections in 7āÆdays as opposed to 20āÆdays for untreated rats. The transfersome-entrapped phage cocktail protected all test animals with no deaths, even when administered with a delay of 12āÆh post-infection, unlike free phages (77).
However, high-pressure homogenization or sonication used during SLN and niosome production can shear phage tails, and the high cost of pharmaceutical-grade lipids limits economic viability for food-animal applications (74, 78). PEGylated liposomes have been explored to prolong circulation time by protecting against clearance by the reticuloendothelial system, but rapid opsonization remains a concern after repeated dosing (75, 79).
To improve intestinal targeting, lipid nanoparticles have been surface-decorated with ligands such as lectins that bind to intestinal M cells, facilitating transcytosis. The small size of liposomes is suitable for cellular uptake, and the presence of cholesterol and PEG can protect against clearing by the reticuloendothelial system, improving circulation time (75). While promising, the immunogenicity of surface modifications and their potential effects on gut homeostasis must be carefully evaluated in target livestock species before field application.
3.2.4 Advanced biomaterials (hydrogels, lipid vesicles, polymeric matrices)
Beyond simple capsules, stimuli-responsive hydrogels are being engineered to release phages in response to environmental triggers such as pH changes or bacterial presence. For veterinary applications, injectable thermosensitive hydrogels have been developed for topical and localized phage delivery.
PluronicĀ® F-127 (Poloxamer 407) is one of the most studied thermosensitive gelling agents for phage delivery (80). Mukhopadhyay et al. (80) developed thermosensitive hydrogels containing varying amounts of PF-127 (15ā20% w/w) modified with hydroxypropyl methylcellulose (HPMC) for delivering a phageāantibiotic combination against Acinetobacter baumannii wound infections. Most hydrogel formulations had a gelation temperature around skin temperature, making them suitable for topical application. The solidified gels released encapsulated phages and colistin in a sustained manner, achieving a 5.66 log reduction in planktonic bacteria and a 3-log reduction in biofilms. The formulation demonstrated good storage stability with negligible activity loss after 9āÆmonths at 4āÆĀ°C. In an ex vivo porcine skin wound infection model, the hydrogel formulation significantly reduced bacterial burden by 4.65 log (80).
For oral delivery, pH-responsive hydrogel microspheres have been designed to protect phages from gastric conditions and release them in the intestine. Yang et al. (81) used electrohydrodynamic spraying to create double-responsive hydrogel microspheres (HMs) made of sodium alginate, hyaluronic acid, and Eudragit S100. For a mixture of Salmonella phages, these microspheres had an encapsulation effectiveness of 90%. The formulation allowed for responsive payload release in the colon, extended intestinal retention, and greatly shielded phages from stomach conditions. HMs-encapsulated phages decreased intestine STm burden by about 2000 times and proinflammatory cytokines (TNF-α, IL-6, and IL-1β) to 60% of those in the infected group in a mouse model of colitis caused by Salmonella Typhimurium. Interestingly, the targeted phage administration avoided antibiotic-associated microbiota dysbiosis and diarrhea by specifically targeting STm and achieving antibacterial activity comparable to ciprofloxacin (81).
Hydrogels have also been investigated as phage-eluting wound dressings in livestock models. A study using Gum Karaya polysaccharide-based hydrogels supplemented with Pseudomonas aeruginosa phages (Pbunavirus MB501 and Phikmvvirus LUZ19) in a porcine deep wound infection model demonstrated a significant synergistic effect. In treated pigs, bacterial load decreased from 7.8āÆĀ±āÆ0.4 log CFU/g to 5.1āÆĀ±āÆ0.8 log CFU/g of tissue, representing a 2.7 log reduction, compared to a 1.0 log reduction in untreated controls. No adverse effects of the GK hydrogels or phage preparations were observed during the study (82).
Similarly, in a porcine deep wound infection model, an injectable Gum Karaya hydrogel formulation containing Staphylococcus phage 812āÆK1/420 (Kayvirus genus) was tested against methicillin-resistant Staphylococcus aureus (MRSA). Within a week, the bacterial load was significantly reduced (2.5 log CFU/g of tissue) as a result of the combined treatmentās synergistic effect. By day eight, there was a noticeable decrease in the local signs of inflammation, along with wound contraction and re-epithelialization (82).
Carrageenan-based hydrogels have also been developed as phage delivery systems. Narayanan et al. (83) fabricated hydrogel wound dressings using the marine polysaccharide carrageenan to immobilize lytic coliphage vB_Eco2571-YU1 against pathogenic E. coli. The immobilized phage showed a sharp decline in bacterial growth during the log phase and, importantly, did not allow for the acquisition of phage resistance by the E. coli strain, unlike unimmobilized phages which developed resistance within 9āÆh. The hydrogels were found to be hemocompatible using a hemolysis assay (83). The comparative advantages, limitations, and representative in vivo data for each formulation technology are summarized in Table 2.
Table 2
| Formulation type | Core materials | Key advantages | Key limitations | Stability in SGF (pH 2, 2āÆh) | Intestinal release | Representative in vivo data | References |
|---|---|---|---|---|---|---|---|
| Liquid suspension | Tris/NaCl buffer, SM buffer, 2ā5% glycerol/sucrose | Low cost, easy preparation, high initial titer; SM buffer preserves infectivity for 30āÆdays at 4āÆĀ°C | No gastric protection; poor thermal stability; not feasible for large-scale water medication | <1% survival | N/A | Reduced diarrhea incidence in piglets; 56.67% survival in zebrafish model | (54, 56, 146) |
| Lyophilized cake | Trehalose + mannitol/skim milk; sucrose + gelatin; whey protein/trehalose | Excellent long-term storage (up to 10āÆmonths at 25āÆĀ°C); sucrose/gelatin maintains viability for 10āÆmonths; cold-chain optional | Hygroscopic; no gastric protection; reconstitution needed; requires desiccants | <5% survival without enteric coating | N/A | 2.0 log10Campylobacter reduction in broilers; 56.67% survival in zebrafish embryo model at MOI 0.1 | (51, 146) |
| Alginate microspheres | Ca-alginate; alginateāpectin (3:1); alginateācarrageenan + CaCO3 | pH-responsive enteric release; mild gelation; biocompatible; ALG-CG-CA shows higher phage recovery in acid | Porous to pepsin; premature dissolution by feed phosphates; rumen microbes degrade alginate | 50ā80% (alginate alone); 85% with alginateāpectin; high recovery with ALG-CG-CA | 60ā80% release in SIF; complete release within 6āÆh at pH 6.8 | 1.2 log10 ileal ETEC reduction in pigs (vs. 2.8 log for direct instillation) | (35, 68, 69) |
| Alginateāchitosan complex | Ca-alginate + chitosan coating; chitosan-alginate-CaClā | Superior acid/enzyme resistance over alginate; >90% SGF survival; complete bile protection | Complex manufacturing; incomplete in vivo release; chitosan requires acetic acid (affects phage survival) | >90% survival (3āÆh in SGF); encapsulated phage decreased only 0.67 log at pH 2.4 | Rapid release (30āÆmin) in SIF; complete release within 6āÆh at pH 6.8 | 3.5 log10S. typhimurium reduction in simulated pig gut; 2.8 log10 faecal reduction in pigs; 3 log Campylobacter reduction in broilers | (35, 68, 110) |
| Spray-dried microcapsules | Trehalose + mannitol + leucine (60:20:20); whey protein + trehalose; trehalose-l-leucine; lactose-leucine | Scalable; high-throughput; survives pelleting (70ā75°C); lactose provides 0.3ā0.4 log loss (better than trehalose 0.5ā0.9 log); FPFāÆ>āÆ50% for inhalation | Outlet temperature stress (50ā70āÆĀ°C); often needs enteric coating; rapid gastric release; leucine alone is poor stabilizer | Poor without coating; depends on excipient composition | Fast release at gastric pH unless enteric-coated | 55% PWD reduction, 40% mortality reduction (1,200 pigs); 3.8 log10Salmonella reduction in broilers; 90% phages survived 2āÆh in SGF | (147ā149) |
| Liposomes/SLNs | Cationic liposomes (phospholipids, cholesterol); DSPC/cholesterol/Tween 80/DOTAP | 100% protection from neutralizing antibodies; enables macrophage entry (94.6% killing of intracellular bacteria); synergistic biofilm eradication with antibiotics | Shear damage during production; costly lipids; immunogenicity (PEGylated); overestimation of encapsulation yield for tailed phages | High protection (3-fold over free phages in bile) | Controlled release | 94.6% killing of intracellular K. pneumoniae in macrophages; liposome-entrapped phage constant titer after 3āÆh antibody exposure; synergistic biofilm eradication with amikacin | (75, 76, 145) |
| In situ-forming hydrogels | Pluronic F-127āÆ+āÆHPMC (14%āÆ+āÆ1.5%); Poloxamer 407 (15ā20% w/w)āÆ+āÆHPMC | Sustained release (24ā72āÆh); thermosensitive (gels at 33āÆĀ°C); 30s gelling time; 10āÆĆāÆviscosity increase upon gelation; easy intramammary instillation | High cost for veterinary market; limited oral applications; complex manufacturing | Not applicable (local delivery) | Not applicable | Improved rabbit keratitis outcomes; 90% bacteriological cure in subclinical S. aureus mastitis (cows); 78% cure in clinical mastitis | (80, 150, 151) |
Comparative overview of formulation technologies for phage cocktails in veterinary medicine.
4 Delivery routes and biopharmaceutical performance
A critical determinant of phage therapy success is the alignment between the chosen delivery route and the formulationās protective features.
4.1 Oral delivery (gavage, feed, drinking water) ā requirements for gastric protection
Oral administration is the most practical route for mass medication in poultry and swine. Gavage is used to obtain accurate doses in experimental situations but not on farms. Feed and water ad libitum delivery are standard and thus phages are subjected to the highest physicochemical stresses, such as gastric acid, pepsin, bile, intestinal enzymes and, in the case of feed, thermal pelleting. Therefore, gastric acid protection (enteric coating/encapsulation) and water stability for 24ā48āÆh at ambient temperature is required for oral formulations (12).
Farm drinking water quality is frequently neglected. Residual chlorine disinfection can kill phages and organic material in water troughs can bind the phages, thus decreasing the actual dose of the animal. Thus, water-stable excipients, like sugars and salts, are essential for the stability of phages in medicated water lines. Kim et al. (56) formulated a stabilizing solution using sugars and salts, which was able to stabilize the phages for up to 48āÆweeks in distilled water at room temperature.
Despite impressive in vitro survival data, oral phage cocktails often achieve only modest intestinal colonization and variable pathogen reductions in vivo. This difference can be explained by several reasons: the first is that in young animals, the transit time through the gastrointestinal tract is short, which decreases the time for the phage to be released from the capsule; the second is that the volume of fluid in the large intestine is high, which would cause the phage to be diluted; the third is that the commensal microbiome which inhabits the gut would compete for receptor sites or produce inhibitory metabolites; and the fourth is that the local concentration of the phage would not be sufficient to cross the replication threshold (inundation threshold) in the entire gastrointestinal tract (84, 85). Fujimotoās (86) study of the significance of phage therapy for controlling intestine commensal infections has revealed that the intestinal system is a special anaerobic environment in which phages are highly specific with regard to their host bacteria.
In a retrospective observational study of 100 consecutive cases of personalized phage therapy, Pirnay et al. (84) showed that phage resistance and phage immune neutralization were documented in patients, with 38.5% of patients screened for phage immune neutralization. Moreover, the study showed that 77.2 and 61.3% of infections, respectively, had clinical improvement and elimination of the targeted bacteria, indicating that phage therapy could be used in combination with antibiotics to achieve positive results.
The dose-volume relationship is also important; when phages are administered in a small volume of concentrated slurry, their survival in the stomach is greater than when administered in large volume drinking water due to the lower surface area to volume ratio and faster gastric emptying of liquids, allowing for less time to be exposed to the stomachās acid.
4.2 Parenteral administration (IM, SC) ā sterility and systemic distribution
Intramuscular (IM) or subcutaneous (SC) injection bypasses gastrointestinal barriers and is suitable for systemic infections or infections at confined sites (e.g., respiratory infections in cattle, septicemia in poultry). The sterilization and apyrogenicity of the phage preparation is of utmost importance, and the endotoxin removal from phage lysates should be validated to below regulatory limits such as <5 EU/kg body weight for intravenous applications (87).
A number of methods for eliminating endotoxins from phage preparations have been reported. In their investigation of polyethylene glycol (PEG)-NaCl precipitation as a scalable technique for endotoxin separation from phage M13, Branston et al. (88) showed that supplementing with up to 2% (v/v) Triton X-100 resulted in a 5.7 log10 reduction in endotoxin concentration over three rounds of precipitation while retaining more than 97% of the phage. When it comes to removing endotoxins from protein solutions, this approach is comparable to the well-known Triton X-114 aqueous two-phase system methodology (88).
Van Belleghem et al. (87) conducted a thorough investigation that examined seven distinct endotoxin removal techniques for five phages (one Staphylococcus aureus phage and four Pseudomonas aeruginosa phages). They showed that the strongest reduction, with an endotoxin removal effectiveness of up to 99%, was achieved by CsCl density purification at an initial concentration of 1012ā1013 PFU/mL. Other purification techniques produced varying efficacy (23ā99%) and occasionally caused significant phage titer reductions (87).
In a retrospective observational analysis of 100 consecutive cases of individualized phage therapy, Pirnay et al. (84) found that 38.5% of screened patients had phage immune neutralization, and 43.8% of reviewed patients had in vivo selection of phage resistance. In 77.2 and 61.3% of infections, respectively, there was clinical improvement and eradication of the targeted bacteria; the likelihood of eradication was 70% lower in the absence of concurrent antibiotics.
While parenteral delivery ensures that 100% of the dose reaches systemic circulation initially, rapid clearance by the liver and spleen limits the plasma half-life. Merril et al. (45) showed that the ability of mammalian host defense systems, specifically the reticuloendothelial systemās organs, to eliminate phage particles from the circulatory system hindered the therapeutic use of phages. They created a serial-passage method in mice to select for phage mutants that could stay in the circulatory system for longer in order to solve this. Using this method, they were able to isolate long-circulating mutants of Salmonella phage P22 and Escherichia coli phage lambda, showing that these mutants were more effective as antibacterial agents than the corresponding original strain in bacteremic mice. The relevant mutation changed the primary phage head protein E, according to a comparison of the parental and mutant lambda capsid proteins (45).
More recent studies have confirmed rapid clearance kinetics in large animal models. In a sheep model of fracture-related infection, Peez et al. (89) assessed phage pharmacokinetics and found that phages were quickly removed from circulation following intravenous delivery, with no phage remaining after 240āÆmin. Phage neutralization accelerated in infected hosts, reaching maximum levels by day 13 compared to day 50 in non-infected animals, and increased during therapy, peaking at 99.9% by the end of treatment.
Moreover, repeated parenteral administration induces phage-neutralizing antibodies (IgG and IgM), which can abrogate therapeutic efficacy upon subsequent dosing. A study on intranasal versus intraperitoneal phage delivery for Pseudomonas aeruginosa lung infections demonstrated that intraperitoneal administration triggered significant IgG, IgM, and IgA production and resulted in decreased survival, whereas intranasal delivery elicited undetectable antibody responses and significantly improved survival (90). This highlights that the route of administration profoundly influences the development of antibody-mediated neutralization, with localized delivery routes potentially overcoming this limitation.
In poultry, in ovo injection of phages has shown promise for controlling bacterial infections. A 2025 study evaluating Salmonella phage administration via the in ovo route in broiler chickens reported that phage-inoculated eggs had a hatching rate of 96.97%, with no significant differences compared to non-inoculated controls. Phage detection rates in cecum samples ranged from 57.14 to 87.50% depending on the inoculation site, with average phage titers of 3.66 to 4.98 log10 PFU/sample (91).
Localized injection at the infection site can achieve high tissue concentrations while reducing systemic exposure. A study by Cheetham et al. (92) on Dichelobacter nodosus, the causative agent of ovine footrot, identified the bacteriophage DinoHI and its interactions with integrated genetic elements that modulate virulence, providing a foundation for phage therapy development against this pathogen.
4.3 Intramammary infusion ā localized delivery for mastitis
Bovine mastitis, predominantly caused by S. aureus, Streptococcus uberis, and E. coli, is a major target for phage therapy. Intramammary infusion deposits phages directly into the mammary gland cistern, achieving high local concentrations while minimizing systemic exposure (93).
The milk environment presents unique challenges for phage therapy. Milk is a complex medium composed of lipids, milk proteins (caseins, whey proteins), and an endogenous bacterial flora. Previous studies have demonstrated that heat treatment (UHTāÆ>āÆpasteurized) and skimming of milk have a positive effect on the bactericidal activity of phages, suggesting an inhibition of phage binding ability to host cells in raw milk, mainly attributed to lipids and whey proteins (94). Titze and Krƶmker (94) investigated the bactericidal activity of obligately lytic phages against S. aureus in pasteurized and raw milk, demonstrating that phage efficacy is significantly influenced by the milk matrix.
The efficacy of phage therapy for intramammary infections has been demonstrated in several model systems. Local intramammary treatment is tolerated and may enhance bacteriological cure compared to non-treatment, according to randomized, negative-controlled pilot research assessing a S. aureus bacteriophage cocktail given locally to the mammary gland in calves. The study concluded that intramammary treatment with bacteriophages has great potential as it is safe and free of antimicrobial residues (93).
When vB_EcoM-UFV13 was administered intramammary against mammary pathogenic E. coli (MPEC) in a murine mastitis model, the bacterial burden was reduced 10-fold. Following viral therapy, pro-inflammatory cytokines such TNF-α and IL-6 were found, suggesting immunological activation (95).
For Streptococcus uberis mastitis, studies have characterized phages with lytic activity against clinical isolates. Phages CP1 and CP2 each reduced S. uberis counts by 86 and 83%, respectively, in lethal dose assays. Phage replication cycles were observed to take between 50 and 60āÆmin (96).
Engineered endolysins have also shown promise for bovine mastitis treatment. A top candidate endolysin developed against streptococcal mastitis pathogens demonstrated a 4.0 log killing efficacy against S. uberis, with similar activity against S. agalactiae and S. dysgalactiae, and showed intracellular activity in bovine mammary epithelial cell lines (97).
4.4 Aerosol/spray ā respiratory delivery
For respiratory pathogens such as Actinobacillus pleuropneumoniae in swine and Mannheimia haemolytica in cattle, aerosolized phage delivery can target the lung mucosa directly. Phage aerosols must be formulated to withstand the shear forces of nebulization and desiccation in the air stream.
The choice of nebulizer type significantly impacts phage viability during aerosolization. A comprehensive study by Cao et al. (98) demonstrated that liposome-encapsulated phages preserved viability during nebulization, with titer losses below 0.4 log10 for encapsulated phages, while non-encapsulated phages experienced titer reductions of up to 1.23 log10, especially during jet nebulization. Vibrating mesh nebulization achieved higher phage recovery (>90%) and respirable fractions (>70%), which are desirable for lung deposition (98).
Astudillo et al. (99) evaluated the structural effects of three distinct nebulizer typesāair-jet, vibrating-mesh, and static-meshāon the structural stability of a Myoviridae phage (PEV44) active against Pseudomonas aeruginosa using transmission electron microscopy. Following nebulization, the percentage of ābrokenā phages (capsid split from tail) increased dramatically; the air-jet nebulizer caused more damage (83% broken) than mesh-type nebulizers (50ā60%) (99). Phage shape was found to be a crucial component, with survival during aerosolization being determined by the integrity of the capsid and tail. For larger, tailed phages, jet nebulizers were shown to preserve a higher proportion of viable phages, whereas vibrating mesh nebulizers more effectively delivered tailless phages (100).
Nebulization has been demonstrated to be protected by encapsulation strategies. The encapsulation efficiency of short-tail phages and long-tail phages was 77.9 and 89.9%, respectively, after lipid-based encapsulation with DSPC, cholesterol, Tween 80 and DOTAP. The inactivation of phages was significant for unbound phages and modest for encapsulated phages (<0.4 log10) (98).
Formulations of phage powder for lung delivery have been developed. An additional study involved the addition of Phage vB_AbaM-IME-AB406 to dry powders of trehalose, mannitol, and L-leucine, demonstrating that mannitol increased the dispersibility of the phage and provided storage stability with less than one log titer loss after 6āÆmonths at high excipient concentration (101).
In poultry, a trial was conducted to assess the efficacy of aerosol spray of bacteriophage to reduce mortality of broiler chickens due to E. coli respiratory infection and it was found that aerosol spray of phage can significantly reduce mortality. Aerosol phage treatment was found to be effective in a severe infection model, with 104āÆCFU being injected into the thoracic air sac, where mortality was reduced from 50 to 20% upon treatment immediately after challenge. Phage have also been shown to be effective at reducing mortality when administered immediately after challenge, with a 53 to 17% reduction in deaths (102, 103) after intramuscular injection. The relative inefficiency of spray treatment as compared to intramuscular injection, however, was attributed to the failure to achieve high levels of phage in the blood using the spray delivery system (103).
Large animal models of respiratory pathogens have been developed. The aerosol challenge model for M. haemolytica pneumonia in colostrum-deprived calves was validated, and consistently induced bronchopneumonia with typical lesions after aerosol challenge with 1āÆĆāÆ1010āÆCFU (104).
There is potential for aerosol delivery of phage for livestock respiratory infections, as it has been shown to be technically possible for phage to survive during nebulization and could be used for prophylactic and therapeutic purposes (98). There are still issues to be addressed, such as structural damage to phages during nebulisation, swift clearance from the respiratory tract, and the need for optimized formulations and delivery devices specific to the morphology of the phages (100).
4.5 Comparative analysis of delivery vs. formulation requirements
A comparative synthesis shows that there is no universal formulation, each delivery route requires specific protection. Enteric-coated and thermostable products are required for oral formulations, products that are ultrapure and endotoxin low are needed for injectables, products with bioadhesive sustained release properties are beneficial for intramammary formulations, and products that do not desiccate or shear are required for aerosols. One major error in the early translational research was the use of a single āstableā liquid formulation for all routes, resulting in different efficacy reports. It highlights the importance of considering on-farm delivery logistics in the development of pharmaceuticals. The different production routes of bacteriophage cocktails in various animal species are shown in Figure 3.
Figure 3
The regulatory pathways are route specific and greatly impact development timelines and costs. The sterility and endotoxin specifications for parenteral products are more stringent than those for aerosols used topically or intramammary infusions (105). Veterinary phage therapies are regulated in the EU by Regulation (EU) 2019/6, and the EMA has developed guidelines on quality, safety and efficacy (105). Phage products can be under FDA (therapeutic) or USDA (food safety) control in the USA (105). The regulatory harmonization of phages remains a key challenge, as they might be classified as veterinary medical products, magistral preparations, food additives, or biocides, none of which were designed for phage-based products (11). Flexibility is provided by the EMA and EDQM but there are some concerns regarding the manufacturing feasibility at commercially viable costs (11, 105).
There are few and still needed costābenefit analyses. At the poultry level, an analysis of the cost of AI-guided phage therapy in broiler chickens estimated the cost at 2āÆĆāÆto 10āÆĆāÆthe antibiotic baseline, ranging from $0.10 to $0.50 per bird, compared to $0.05 per bird for antibiotics (106). These extra costs have to be compensated by improvements in productivity in terms of reduction in mortality (0.2ā3%), feed conversion ratio (0.2ā3%) and weight gain (0.1ā2%) (106). The cost-effectiveness of phage therapy has yet to be proven in aquaculture.
The need of the hour is for a unified regulatory framework that can accommodate the unique biological characteristics of phages in different delivery modes, to speed up commercial translation (84). As Pirnay et al. (84) pointed out, frameworks should enable defined phage products and personalized strategies, both alone and in combination with other antimicrobials.
5 Therapeutic outcomes in major production species
5.1 Poultry (broilers and layers)
Poultry, particularly broilers, have been the most extensively studied species for oral phage therapy due to the economic importance of Salmonella and Campylobacter control and the feasibility of water/feed medication.
A systematic review and meta-analysis of 20 studies that investigated the effect of phage on the reduction of Salmonella spp. in poultry meat, revealed an overall Salmonella spp. reduction rate of 1.729 log CFU/cm2 (95% CI: 1.548ā1.910) (107). The study revealed that the activity of phages increases with time and the concentration of Salmonella decreases with an increasing dose of bacteria and phages. It was discovered that phage therapy worked better against S. enteritidis than against other species (107).
Phage efficacy has been greatly enhanced by the use of encapsulation. The antibacterial activity of chitosan/alginate films loaded with Salmonella phages was successfully confirmed when the films were stacked layer-by-layer, which resulted in the reduction of Salmonella counts on contaminated chicken meat at pH 7.0 (108). The ability of alginate to increase gastrointestinal stability and bactericidal activity of oral Salmonella phage cocktails in poultry feed has been demonstrated, and a recent study confirmed that alginate can improve the survival of phages in the digestive tract of poultry (109).
A lot of research has been done on phage therapy for Campylobacter. Wagenaar et al. (110) demonstrated that phage therapy in broilers resulted in a significant reduction in the counts of C. jejuni at the initial stage followed by a stabilization of the bacterial counts after 5āÆdays at a level 1 log lower than the control group. The preventive groups had a delay in colonization, and a first log reduction, according to Wagenaar et al. (110).
According to a more recent study by Peh et al. (111), a phage cocktail containing group II and III phages dramatically decreased fecal Campylobacter excretion and Campylobacter concentrations in the colon of broilers. Using a targeted development method, the study refined phage cocktails, demonstrating that mixing phages leads to greatly increased lytic activity. This was effectively translated into practical application in settings similar to field conditions (111).
The emergence of phage resistance remains a challenge. Scott et al. demonstrated that in broiler chickens treated with lytic bacteriophages, Campylobacter isolates surviving phage predation exhibited genomic rearrangements, including intra-genomic inversions of up to 590āÆkb (one-third of the genome) (112). These rearrangements conferred three phenotypes: resistance to virulent bacteriophage infection, inefficient colonization of the broiler chicken intestine, and production of infectious bacteriophage CampMu (112). Critically, the inability to replicate bacteriophage was associated with a significant fitness cost that rendered resistant strains competitive only in the presence of bacteriophage (113).
Bacteriophage supplementation has been associated with improved growth performance in broilers. Studies have reported that bacteriophage supplementation enhances growth performance by increasing body weight gain, improving feed efficiency, and positively modulating gut microbiota by killing targeted pathogens while promoting beneficial commensal bacteria. The narrow host range of most phages minimizes off-target effects on commensal bacteria, though cocktails containing broad-host-range phages warrant further investigation.
5.2 Swine
In swine, the primary targets for phage therapy are enterotoxigenic E. coli (ETEC) causing post-weaning diarrhea (PWD) and Salmonella Typhimurium.
A meta-analysis of 11 challenge studies involving 198 piglets quantified the effects of bacteriophage therapy on bacterial load. Prophylactic dosing produced a moderate and highly consistent reduction (SMDāÆ=āÆā0.64, pāÆ<āÆ0.001; I2āÆ=āÆ19.41%), whereas therapeutic dosing produced a larger but more variable effect (SMDāÆ=āÆā1.29, pāÆ<āÆ0.001; I2āÆ=āÆ66.77%). Reductions were significant for both E. coli (SMDāÆ=āÆā0.79, pāÆ=āÆ0.014) and Salmonella (SMDāÆ=āÆā0.90, pāÆ<āÆ0.001) models. Encapsulated phages produced larger reductions than non-encapsulated formulations (SMDāÆ=āÆā1.51, pāÆ=āÆ0.026 vs. SMDāÆ=āÆā0.70, pāÆ<āÆ0.001), although the moderator test was not significant. In-feed delivery yielded more consistent outcomes than oral gavage (I2āÆ=āÆ21.98% vs. 63.91%) (114).
An updated review by Chen et al. (115) systematically examined bacteriophage applications in weaned piglets, confirming that phages can provide practical guidance for controlling diarrhea and intestinal health problems. The review highlighted that several studies have demonstrated the efficacy of phages in mitigating pathogen phenotypes in piglets, including ETEC-specific bacteriophage reducing diarrhea percentage.
Microencapsulation has been shown to improve phage stability and delivery in swine. Dlamini et al. (116) demonstrated that alginateācarrageenan encapsulation with 1% (w/v) CaCO3 significantly improved phage viability at pH 2ā2.5, reducing phage loss to <0.5 log10 PFU/mL even after 1āÆh at pH 2. Phages were efficiently released from microcapsules following a shift to neutral pH (7.5), simulating passage to the duodenum.
Ten phages from the Siphoviridae and Myoviridae families were used to create an anti-Salmonella phage cocktail. Microencapsulation using sodium-alginate-based techniques reduced the cocktail titer by just 1.0ā1.5 logs (premicroencapsulation: 10.4 log10 PFU/mL; postmicroencapsulation method one: 9.2 log10 PFU/mL; postmicroencapsulation method two: 8.9 log10 PFU/mL). For up to 14āÆdays, microencapsulated phages did not significantly decrease in titer at either 4āÆĀ°C or 22āÆĀ°C (117).
Bacteriophages may be a viable substitute for antibiotics and might be used to enhance pig growth performance, according to an in vivo evaluation of bacteriophages specific to multidrug-resistant E. coli on fecal bacterial counts and microbiota in nursery pigs. Salmonella colonization in pigs has been demonstrated to be decreased by direct feeding of microencapsulated bacteriophages (118).
The long-term evolutionary consequences of phage therapy in swine have been examined. Research on bacteriophage resistance mechanisms has identified that resistant mutants may carry mutations in lipopolysaccharide (LPS) core biosynthetic genes such as waaG and waaQ (119). These mutants are often outcompeted by wild-type strains in the absence of phages, indicating a significant fitness cost that might be exploited therapeutically.
5.3 Ruminants (bovine: dairy and beef)
Phage therapy in adult ruminants faces the formidable barrier of the forestomachārumen, reticulum, and omasumāwhose microbial density and complex biochemistry can rapidly inactivate or outcompete introduced phages.
Early attempts to orally deliver phage cocktails against E. coli O157: H7 in cattle met with limited success. Bach et al. (120) showed that although three lytic E. coli O157 phages (rV5, wV8, and wV11) could survive in ruminal fluid from cattle fed forage and concentrate for a full day, there was no discernible lytic activity against E. coli O157: H7 in ruminal batch cultures, and none of the phages changed fermentation parameters. In vivo studies have similarly reported that phages could be recovered in the rumen but declined over time (approximately 92āÆh), with shedding varying between animals (121).
The rumen presents unique challenges for phage therapy. Research on alginate-chitosan microbeads and thermos-responsive hydrogels for phage delivery has demonstrated that release kinetics from biomaterials are impacted by both the biomaterial and the phages themselves (122). Studies have shown potential for local delivery of phages using hydrogels, with results indicating that phage release kinetics can be modulated for both rapid burst release and controlled, extended release (122).
Local administration has shown far greater success in ruminants. A randomized, negative-controlled pilot study evaluating an intramammary S. aureus bacteriophage cocktail in dairy cows reported that local intramammary treatment was well-tolerated and may improve bacteriological cure compared to non-treatment (93). Due to their safety and lack of antibiotic residues, the use of bacteriophages to treat intramammary infections has enormous potential (93). 23 udder quarters infected with S. aureus were randomly assigned to a treatment group (nāÆ=āÆ16) and a control group (nāÆ=āÆ7) in a later effectiveness study conducted on a different farm. Five intramammary infusions of the phage mixture were administered to the treatment group at intervals of 12āÆhours. As a result, the treatment groupās bacteriological cure rate was 81.3% (13/16), while the control groupās was 28.6% (2/7) (pāÆ=āÆ0.026) (93).
In 24 clinical instances of cattle with staphylococcal mastitis, Gautam et al. (123) compared the therapeutic efficiency of intramammary bacteriophage with antibiotic therapy. Four treatment groups were randomly assigned to the animals: simultaneous therapy (T4), antibiotic alone (T1), bacteriophage followed by antibiotic 8āÆhours later (T2), and antibiotic followed by bacteriophage 8āÆhours later (T3). The sequential bacteriophage then antibiotic group (T2) had the highest recovery rate (83.33% (5/6)), followed by T4 and T3, while antibiotic alone (T1) had the lowest efficacy (123). This method may aid in lowering antibiotic resistance in dairy cattle and provides a viable alternative for the treatment of staphylococcal mastitis (123).
The lytic effectiveness of bacteriophages against S. aureus isolates from bovine mastitis was examined by Titze et al. (124). Three phages (STA1. ST29, EB1. ST11, and EB1. ST27) make up the phage mixture, which was able to lower the density of S. aureus bacteria in pasteurized milk, and it was still able to do so in raw milk, but to a lesser extent than in pasteurized milk. At least one of the tested phages was able to lyse nearly two thirds of the 92 isolates that were examined (124).
A notable exception to the rumen barrier is the neonatal calf, whose rumen is not yet functional and whose gastric pH (abomasum) is comparable to that of monogastrics. Bacteriophage supplementation in pre-weaned dairy calves has been shown to reduce the duration of neonatal diarrhea. A study of 200 Holstein Ć Gyr crossbred female calves divided into control (no supplementation) and phage groups (1āÆg/day from day 3 to day 70 of life) reported that the phage group had fewer days with diarrhea (PHAGE: 4.68āÆdays, CON: 6.61āÆdays; pāÆ=āÆ0.03) (125). The average daily gain of the phage group was higher up to 80āÆdays of life (pāÆ<āÆ0.05), and fecal samples of three animals in the phage group (vs. nine in control) were positive for E. coli after PCR tests (125).
PhageLab, in partnership with MSD Animal Health, has launched PHAGEIN in Brazil, a cutting-edge biotechnology solution for managing calf health that leverages bacteriophages to selectively target pathogenic bacteria such as E. coli and Salmonella while preserving beneficial gut microbiota (126). This represents a significant commercial milestone, indicating that oral phage therapy for enteric infections in pre-ruminant calves is a viable, commercially relevant niche (126).
For bovine respiratory disease (BRD), phage-derived endolysins have shown promise. Moqaddes (127) engineered bacteriophage-derived endolysins, either unmodified or fused to polycationic nanopeptides (PCNPs), and evaluated their activity against Mannheimia haemolytica. While native endolysins exhibited strong muralytic activity, PCNP-fused endolysins showed greater antibacterial activity, achieving up to 4.5 log10 reductions in viable bacteria, particularly with EDTA (127). However, conventional phage isolation and plaque assays using BRD-associated clinical samples failed to recover active lytic phages, suggesting that prophages or extensive antiviral defense systems may restrict phage recovery (127).
The induction of an anti-phage response did not significantly affect antibacterial efficacy, according to a study on anti-phage antibodies in calf sera after treatment of E. coli and M. haemolytica-specific bacteriophages. Improvements in health status, a protective impact that persisted for at least 3āÆweeks following the last phage dose, and a notable decrease in pathogenic E. coli in feces and M. haemolytica in calveās nasal cavities were among the measurable benefits (128).
5.4 Aquaculture (salmon and shrimp)
Aquaculture species present unique delivery challenges because phages are administered in an aqueous environment where dilution is immediate and continuous. In flow-through or recirculating aquaculture systems, phage titers decline rapidly due to water exchange, UV disinfection, and adsorption to particulate matter.
In marine shrimp (Litopenaeus vannamei), phage therapy against Vibrio parahaemolyticus causing acute hepatopancreatic necrosis disease (AHPND) has been investigated. Bacteriophages can impact bacteria through a variety of processes, such as lowering bacterial concentration through the lytic process or altering genes encoding bacterial pathogenicity, according to a 2024 study on Vibrio spp. phages isolated from shrimp farming in the Mekong Delta (129). Phage KG6 decreased bacterial abundance without altering gene sequences, however phages ST9 and ST10 altered nucleotides at four locations in comparison to the V. parahaemolyticus sequence (129). If such effects can lessen or negate bacterial pathogenicity, these findings open up new avenues for phage therapy research (129).
Ecology and evolution of Vibrio phage interactions have been studied in great detail in natural populations. In recent years, the field of Vibrio phage research has seen significant progress, with high-throughput assays and genomic tools providing new insights into the specificity and host range of Vibrio phages and the evolutionary dynamics driving these interactions (130). One of the key discoveries is that mobile genetic elements (MGEs) encode bacterial defense systems that influence the coevolution of phages and bacteria. The discovery of such a phage satellite as PICMI highlights the role of MGEs in the transfer of antiviral systems, which has an impact on ecological and evolutionary dynamics (130). The paradox of the generalist Vibrio phages, which are rare but have wide hosts, is also discussed (130).
Bernard et al. (131) investigated the genome of a Vibrio crassostreae host, and the genomes of the associated Schizotequatroviruses, from an oyster farm. The conserved genomic architecture of these phages, with broad host ranges, is interrupted by recombination hotspots. Importantly, some strains were found to be evolutionarily flexible, with the ability to switch from ompK to lamB (131). Although the host range is broad, there were few reports of schizotequatroviruses in the environment. This may be because of ecological constraints or fitness costs, including their preference for generalist Vibrios in seawater, or for the patho-phylotypes selected for oyster farms (131). These discoveries lay the groundwork for upcoming phage applications in aquaculture and shed light on the genetic and ecological trade-offs influencing Schizotequatrovirus generalism (131).
Deng et al. (132) analyzed the coexistence strategies of phage-prokaryote in shrimp culture pond ecosystems, and found that the interactions between phages and prokaryotes regulate the diversity of microbial community in the intestine and sediment microhabitats (132). The knowledge of this ecological aspect is essential for the design of efficient phage-based intervention in aquaculture (132).
The genetic structure of the host populations is represented by the Vibrio phage interaction networks (133). Environmental Vibrio phage research has revealed these interactions are highly modular and are regulated by a specific matching between genus of Vibrio phage and clades of Vibrio. After adsorption, intracellular defense mechanisms further restrict the number of strains that can be successfully infected and lysed (133).
Various routes of phage therapy have been tested for salmonids. Aeromonas salmonicida subspecies salmonicida have been isolated from aquaculture settings; studies have been conducted on the polyphasic identification of A. salmonicida and virulence characterization (134). A careful analysis of these species-specific results clearly shows that when the formulation and delivery method is carefully tailored to the digestive physiology of the animal and the niche of the pathogen, phage cocktails can provide clinically significant reductions of pathogen load and mortality. On the other hand, failures are often due to the failure to consider the dynamic in vivo environment: the stability of the in vitro environment is assumed to be the same as that of the intestinal environment, or the in vitro encapsulation is assumed to be stable in the aquatic environment. Table 3 summarizes the therapeutic outcomes of phage cocktail applications across major production species, including poultry, swine, ruminants, and aquaculture, with key clinical endpoints and practical considerations.
Table 3
| Species | Target pathogen(s) | Delivery route & formulation | Key clinical endpoint (magnitude) | Practical considerations | Reference |
|---|---|---|---|---|---|
| Broilers | Salmonella Enteritidis | Oral gavage, drinking water, aerosol spray (107 PFU/mL) | Prophylactic: 1.92 log10 reduction (Day 3); Drinking water: 1.62 log10; Aerosol: 1.12 log10 (least effective) | Prophylactic administration most effective; aerosol spray least effective; route of delivery significantly impacts efficacy | (152) |
| Broilers | Salmonella spp. | Phage cocktail in feed/water | 1.0ā1.4 log10 CFU/g reduction in cecal contents; improved weight gain | Treatment improved weight gain; effective for reducing target bacteria colonization | (15) |
| Piglets | ETEC K88 (F4) | Phage cocktail (oral) | 19.2% lower cumulative diarrhea burden (pāÆ=āÆ0.044); 61.9% higher average daily gain (pāÆ=āÆ0.065); significant E. coli reduction (pāÆ=āÆ0.009) | Phage therapy shows potential as antibiotic alternative; no major shifts in microbial diversity; phage replication detected in feces | (153) |
| Piglets | ETEC | Phage cocktail (prophylactic) | Prophylactic dosing produced moderate and highly consistent reduction (SMDāÆ=āÆā0.64, pāÆ<āÆ0.001; I2āÆ=āÆ19.41%); encapsulated phages: SMDāÆ=āÆā1.51 (pāÆ=āÆ0.026) vs. non-encapsulated: SMDāÆ=āÆā0.70 (pāÆ<āÆ0.001) | Prophylactic more consistent than therapeutic; in-feed delivery more consistent than oral gavage; encapsulation improves efficacy | (114) |
| Dairy Cows | S. aureus (mastitis) | Intramammary phage cocktail (5 infusions at 12-h intervals) | 81.3% (13/16) bacteriological cure rate vs. 28.6% (2/7) in control group (pāÆ=āÆ0.026) | Safe and free of antimicrobial residues; well-tolerated; first negative-controlled in vivo study; larger multicenter studies needed | (93) |
| Beef Cattle | Salmonella spp. | Phage cocktail applied to feedlot pen surface | Significant reduction on cattle hides at Days 14 and 21 (combination treatment most effective) | Pre-harvest intervention may reduce Salmonella populations; combination with water/manure treatments most effective | (154) |
| Aquaculture | Vibrio campbellii | Phage vB_VcaP_R24D and vB_VcaP_R25D | High stability at 4ā45āÆĀ°C and pH 3ā10; robust lytic efficiency during logarithmic growth | Both phages are podovirus morphotypes; short latent period (<10āÆmin); no lysogenic genes or virulence factors; promising biocontrol agents for Vibriosis | (155) |
Summary of therapeutic phage cocktail outcomes in food-producing animals.
6 Challenges and future perspectives
6.1 Scale-up and manufacturing costs
The production of high-titer phage lysates at industrial scale (thousands of liters) is technically feasible, as demonstrated by existing commercial phage products for food safety (e.g., ListShieldā¢, PhageGuard). However, a significant obstacle to the effective launch of phage-based products could be production concerns (135). Regulatory approval depends on the Chemistry, Manufacturing, and Control (CMC) portion of the regulatory dossier; for phage cocktails, the CMC part must specify the manufacturing requirements for each phage as well as the procedure for mixing phages to create the finished product (135). Since regulatory bodies frequently demand that pivotal studies be conducted using products made utilizing the final process, early development of the CMC process is crucial (135).
One important factor is the cost of goods (CoGs). Phage manufacture necessitates isolated GMP manufacturing facilities because to the possibility of contamination, which is a significant capital investment that typically costs between $15 and $25 million USD (135). Furthermore, depending on the indication, those manufacturing facilities may have a very large capacity. For instance, a poultry product would need a lot of doses to treat a sizable fraction of the worldās poultry population (~14 billion birds) (135).
If profitability per animal is low, then the cost per treatment dose should be similar to that of antibiotics or vaccines. Cost reduction is possible due to economies of scale, continuous flow propagation of phages and use of agricultural by-products as fermentation media (135). However, in some cases, producers may not be willing to pay and cost-sharing schemes or regulatory incentives might be needed, e.g., to reduce broiler Salmonella. As reviewed by Hussain et al. (136), encapsulation and delivery technologies are critical for enhancing phage stability and enabling controlled release in the poultry gastrointestinal tract, thereby improving therapeutic efficacy in commercial poultry production. Furthermore, Shakir et al. (137) demonstrated that bacteriophage supplementation in commercial layer flocks improved growth performance and reduced disease burden by elevating immunity levels, suggesting that phage products can be economically viable when integrated into routine poultry health management.
6.2 Regulatory ambiguities (FDA/CVM and EMA guidelines)
The regulatory process of veterinary phage products is still incomplete and unclear (105). Veterinary phage therapies are new therapies that are covered by the EU regulatory framework for veterinary medicinal products (Regulation (EU) 2019/6), which regulates the marketing authorization process (105). The EMA has prepared the āGuideline on the quality, safety and efficacy of veterinary medicinal products specifically designed for phage therapyā which outlines the general requirements for validation of phage efficacy and safety assessment, as well as characterization of phages (105). Furthermore, a general chapter on phage therapy medicinal products for human and veterinary use has been adopted by the European Pharmacopeia (EP) under the title āPhage therapy medicinal products for human and veterinary useā, which defines quality requirements for production and control (105).
An alternative strategy has been developed in the United States where the regulatory status of phage interventions will depend on the intended use of each productāphage products can be regulated by the FDA for therapeutic use or by the USDA for food safety (105).
However, the inherent variability and potential for compositional changes in phage cocktails challenge conventional Chemistry, Manufacturing, and Controls (CMC) paradigms (105). The current regulatory environment is not conducive to the development of phage products and is considered to act as a barrier in many cases. Recent EMA and EDQM guidelines offer some flexibility to account for the biological nature of phages, but concerns remain about the feasibility of manufacturing phage-based products following existing rules for veterinary chemotherapeutants at commercially viable costs (105).
Compassionate use and magistral phage preparations under national pharmacy laws are currently the de facto pathway in Belgium and Poland (84). The lack of harmonized guidelines deters investment and prolongs time to market. A āphage registryā approach, where well-characterized phage components are pre-approved for mixing into custom cocktails, has been proposed as a pragmatic solution (84). Beyond production animals, phage therapy has also been explored in equine medicine. Sarmykova et al. (138) isolated and characterized a Myoviridae bacteriophage specific to Streptococcus equi, the causative agent of horse strangles, which is widespread in Kazakhstan and predominantly affects foals and young horses.
6.3 Emergence of phage resistance against cocktails
Even well-designed cocktails do not eliminate the risk of phage resistance. Long-term treatment can be undermined by bacterial counter-defenses, such as receptor mutations, abortive infection, CRISPR-Cas, and restriction-modification systems (139). Cocktails are far less prone to the emergence of resistance than monophages, however resistance is still a serious problem (9).
A promising strategy is the design of phage cocktail based on cross-resistance. Knowing the cross-resistance pattern allows phages to be clustered by resistance signatures and cocktails to be built by picking representatives of different clusters (140). This will mean that resistance to one phage will not affect another and the therapy will be more effective with less resistance building up. A cocktail of CPD4 and CPD7 phages showed high therapeutic potential against necrotic enteritis caused by C. perfringens in poultry (140).
Immuno-phage synergy is a paradigm change in the treatment of resistance. Pathogenic bacteria typically undergo mutations or shed essential surface structures (such as capsules, LPS, pili) to resist phage infection, at the cost of fitness (141). These compromises significantly improve host immune clearance, such as increased susceptibility to opsonophagocytosis by neutrophils, complement-dependent killing, and host chemical barriers (141). The evolutionary arms race might be changed by leveraging the dynamics of phage-induced selective pressure and immunological trade-offs, and intentionally putting pathogens into āevolutionary traps.ā This strategy will convert the formidable phage resistance to a therapeutic advantage (141).
Costs of fitness of receptor mutations can help to reduce resistance, but this depends on the pathogen and the phage (139). Some of the strategies used are proactive: rotation of cocktail compositions, cocktails with organic acids or probiotics, engineering of phages to target essential bacterial receptors, and cocktails designed to anticipate bacterial resistance trajectories to guide bacterial evolution toward clinically desirable, immune-sensitive phenotypes (141). However, public and trade barriers are present for the regulatory acceptance of genetically engineered phages in food animals. In addition to these strategies, the biofilm matrix represents a further challenge to phage efficacy, as it protects embedded pathogens from lytic agents. Nevertheless, bacteriophages can penetrate the polymeric matrix and lyse biofilm-forming bacteria on food-contact surfaces, thereby improving food safety (142).
6.4 Standardization of titer assays
One of the seemingly trivial but important issues is the absence of a standardized plaque assay procedure in laboratories. The double-layer agar (DLA) method is still considered the standard method for enumerating bacteriophage (141). Uses two layers of agar in a petri dish: one layer for bacteria to grow, and the other layer with bacterial host and phages. Phages spread, enter bacteria and lyse them, creating visible plaques. This approach, however, must be optimized for any specific phage-host combination, and there are potential errors, including contamination, differences in bacterial growth, and operator bias (143).
For the same phage preparation, differences of up to 1 log10 can be obtained depending on the type of agar used, the host strain, the incubation conditions, and the type of double-layer method used. The spot assay on soft agar overlaid with MgSO4 gave reproducible results for phage K and 154 S. aureus strains, highlighting the importance of reproducible media preparation to ensure the accuracy of the results (143). The analytical specificity of the spot assay is, however, inherently limited since susceptibility of the phage remains possible without plaque formation and vice versa (143).
Phage resistance and efficacy of cocktails are influenced by phenotypic heterogeneity. To integrate phage therapy into clinical and veterinary practice, it is crucial to standardize these methods (144).
7 Conclusion
Bacteriophage cocktails represent a transformative approach to combating antimicrobial resistance in veterinary medicine, but their clinical success depends critically on formulation strategies that overcome physicochemical barriers encountered during storage, feed processing, and gastrointestinal transit. This review has demonstrated that encapsulation technologiesāincluding alginate-chitosan microspheres, spray-dried powders, lipid nanoparticles, and thermosensitive hydrogelsācan preserve phage infectivity when tailored to specific delivery routes and target species, yet translation from in vitro stability to in vivo efficacy remains incomplete due to overlooked factors such as gastrointestinal motility, rumen microbial activity in ruminants, and prandial state. The emergence of phage resistance, though mitigated by cocktails, requires proactive strategies including cross-resistance-guided design and exploitation of fitness trade-offs. Future progress demands species-specific physiologically based pharmacokinetic/pharmacodynamic models, regulatory harmonization, standardized titer assays, and economic incentives to accelerate commercial translation. With these advances, phage therapy can transition from a promising experimental intervention to a sustainable pillar of livestock health management, reducing antibiotic dependence and preserving antimicrobial efficacy for future generations.
Statements
Author contributions
MM: Data curation, Visualization, Methodology, Validation, Investigation, Software, Writing ā review & editing, Writing ā original draft, Conceptualization. MT: Writing ā review & editing, Writing ā original draft, Investigation. AS: Writing ā review & editing, Data curation, Validation, Conceptualization, Formal analysis. NN: Writing ā review & editing, Investigation. YQ: Supervision, Writing ā review & editing, Funding acquisition, Project administration, Resources. AK: Supervision, Writing ā review & editing, Validation. FA: Project administration, Funding acquisition, Supervision, Writing ā review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. The researchers would like to thank the Deanship of Graduate Studies and Scientific Research at Qassim University (www.qu.edu.sa) for financial support (QU-APC-2026).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that Generative AI was used in the creation of this manuscript. During the preparation of this manuscript, the authors used DeepSeek V4 for language polishing and BioRender for figure creation. All core research content, including conceptualization, literature analysis, and conclusions, was independently developed by the authors. The AI tools were used solely for linguistic refinement and graphical optimization. All references, factual claims, and figure labels were manually verified by the authors. The alternative text (alt text) for figures was generated with the support of artificial intelligence, and reasonable efforts have been made to ensure accuracy, including review by the authors where possible. The authors take full responsibility for the final published version of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Van BoeckelTPPiresJSilvesterRZhaoCSongJCriscuoloNGet al. Global trends in antimicrobial resistance in animals in low-and middle-income countries. Science. (2019) 365:eaaw1944. doi: 10.1126/science.aaw1944,
2.
KhanAYEffendiMHTyasningsihWUllahSKhanIUShahMKet al. Antimicrobial potential of indigenous medicinal plants against multi drugs resistant enterohemorrhagic Escherichia coli O157 isolated from canine in Pattoki tehsil, Punjab Province, Pakistan. Egypt J Vet Sci. (2025) 56:2997ā3008. doi: 10.21608/ejvs.2025.342425.2543
3.
European Food Safety Authority (EFSA), European Centre for Disease Prevention and Control (ECDC). The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2020/2021. EFSA J. (2023) 21. doi: 10.2903/j.efsa.2023.7867
4.
WHO. Antimicrobial resistance. (2026). Available online at: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance (Accessed October 5, 2026).
5.
SalamMAAl-AminMYSalamMTPawarJSAkhterNRabaanAAet al. Antimicrobial resistance: a growing serious threat for global public health. Healthcare. (2023) 11:1946. doi: 10.3390/healthcare11131946,
6.
KhanAYEffendiMHShaukatAMuneebM. Prevalence, risk factors, and innovative therapies for methicillin-resistant Staphylococcus aureus in livestock and companion animals in Pakistan. Open Vet J. (2026) 16:1438. doi: 10.5455/ovj.2026.v16.i3.3,
7.
YoussefRASakrMMSheblRIAboshanabKM. Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections. Gut Pathog. (2025) 17:60. doi: 10.1186/s13099-025-00735-y,
8.
Torres-BarcelóC. The disparate effects of bacteriophages on antibiotic-resistant bacteria. Emerg Microbes Infect. (2018) 7:1ā12. doi: 10.1038/s41426-018-0169-z,
9.
MuneebMKhanAYShaukatAQuY. Bacteriophage cocktails for combating multidrug-resistant Staphylococcus aureus infections in animals: a comprehensive review across pets, livestock, and wildlife. Microb Pathog. (2026) 219:108774. doi: 10.1016/j.micpath.2026.108774,
10.
KanekoTNakatsukaKTsunedaS. Phage cocktails: state-of-the-art technologies and strategies for effective design. FEMS Microbiol Rev. (2026) 50:fuaf061. doi: 10.1093/femsre/fuaf061,
11.
ToussaintBMunoz-PineiroAPirnayJ. Overview and Outlook of phage Therapy and phage Biocontrol. Luxembourg: Publications Office of the European Union (2024).
12.
RahmanMAAbrahamRHampsonDJAbrahamSUddinJM. Current challenges and potential strategies to enhance efficacy of oral phage therapy in food animals: a systematic review with quantitative analysis. Viruses. (2026) 18:544. doi: 10.3390/v18050544,
13.
JoÅczyk-MatysiakEÅodejNKulaDOwczarekBOrwatFMiÄdzybrodzkiRet al. Factors determining phage stability/activity: challenges in practical phage application. Expert Rev Anti-Infect Ther. (2019) 17:583ā606. doi: 10.1080/14787210.2019.1646126,
14.
Ly-ChatainMH. The factors affecting effectiveness of treatment in phages therapy. Front Microbiol. (2014) 5:51. doi: 10.3389/fmicb.2014.00051,
15.
RahmanMAAbrahamRAbrahamSHampsonDJUddinJM. Application of bacteriophages to control bacterial infections of food animals in the era of antimicrobial resistance: an overview. Vet Microbiol. (2026) 316:110988. doi: 10.1016/j.vetmic.2026.110988,
16.
MerchantHAMcConnellELLiuFRamaswamyCKulkarniRPBasitAWet al. Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. Eur J Pharm Sci. (2011) 42:3ā10. doi: 10.1016/j.ejps.2010.09.019,
17.
FabayRVSerranoAEJrAlejosMSFabayJV. Effects of dietary acidification and acid source on fish growth and feed efficiency. World Acad Sci J. (2022) 4:21. doi: 10.3892/wasj.2022.156
18.
ShymialevichDWójcickiMSokoÅowskaB. The novel concept of synergically combining: high hydrostatic pressure and lytic bacteriophages to eliminate vegetative and spore-forming bacteria in food products. Foods. (2024) 13:2519. doi: 10.3390/foods13162519,
19.
ColomJCano-SarabiaMOteroJCortĆ©sPMaspochDLlagosteraM. Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl Environ Microbiol. (2015) 81:4841ā9. doi: 10.1128/AEM.00812-15,
20.
KaczorowskaJCaseyELugliGAVenturaMClarkeDJvan SinderenDet al. In vitro and in vivo assessment of the potential of Escherichia coli phages to treat infections and survive gastric conditions. Microorganisms. (2021) 9:1869. doi: 10.3390/microorganisms9091869,
21.
LoganathanANachimuthuR. In vitro and in vivo therapeutical efficiency of the staphylococcus phages and the effect of phage infectivity in well-mixed and spatial environment. Biologia. (2023) 78:265ā77. doi: 10.1007/s11756-022-01236-y
22.
PaulAJChandraMKaurGNarangD. Isolation and characterization of lytic bacteriophages against Staphylococcus aureus. Braz J Microbiol. (2025) 56:3059ā70. doi: 10.1007/s42770-025-01793-9,
23.
SĆørensenMCHvan AlphenLBHarboeALiJChristensenBBSzymanskiCMet al. Bacteriophage F336 recognizes the capsular phosphoramidate modification of Campylobacter jejuni NCTC11168. J Bacteriol. (2011) 193:6742ā9. doi: 10.1128/JB.05276-11,
24.
GencayYESĆørensenMCWenzelCQSzymanskiCMBrĆøndstedL. Phase variable expression of a single phage receptor in Campylobacter jejuni NCTC12662 influences sensitivity toward several diverse CPS-dependent phages. Front Microbiol. (2018) 9:82. doi: 10.3389/fmicb.2018.00082,
25.
NobregaFLCostaARSantosJFSiliakusMFVan LentJWKengenSWet al. Genetically manipulated phages with improved pH resistance for oral administration in veterinary medicine. Sci Rep. (2016) 6:39235. doi: 10.1038/srep39235
26.
SamtlebeMDenisSChalanconSAtamerZWagnerNNeveHet al. Bacteriophages as modulator for the human gut microbiota: release from dairy food systems and survival in a dynamic human gastrointestinal model. LWT-Food Sci Technol. (2018) 91:235ā41. doi: 10.1016/j.lwt.2018.01.033
27.
WickeNBedfordMRHowarthM. Gastrobodies are engineered antibody mimetics resilient to pepsin and hydrochloric acid. Commun Biol. (2021) 4:960. doi: 10.1038/s42003-021-02487-2,
28.
YangMYangZEverettDWGilbertEPSinghHYeA. Digestion of food proteins: the role of pepsin. Crit Rev Food Sci Nutr. (2025) 65:6919ā40. doi: 10.1080/10408398.2025.2453096,
29.
MhoneAL. Characterization of Salmonella Enteritidis Bacteriophages and Evaluation of phage Delivery Systems to Increase phage Survival in Simulated Digestive System and Chickens. Doctoral dissertation. Nairobi, Kenya: Jomo Kenyatta University of Agriculture and Technology (JKUAT) (2023).
30.
DiniCIslanGAde UrrazaPJCastroGR. Novel biopolymer matrices for microencapsulation of phages: enhanced protection against acidity and protease activity. Macromol Biosci. (2012) 12:1200ā8. doi: 10.1002/mabi.201200109,
31.
MalikDJSokolovIJVinnerGKMancusoFCinquerruiSVladisavljevicGTet al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interf Sci. (2017) 249:100ā33. doi: 10.1016/j.cis.2017.05.014,
32.
MalikD. Bacteriophage encapsulation using spray drying for phage therapy. Curr Issues Mol Biol. (2021) 40:303ā16. doi: 10.21775/cimb.040.303
33.
BamfordDBamfordJ. Lipid-containing bacteriophage PM2, the type-organism of Corticoviridae. In: The Bacteriophages. Oxford, United Kingdom: Oxford University Press (2006). p. 171ā4.
34.
KrupovicMVilenHBamfordJKKivelƤHMAaltoJMSavilahtiHet al. Genome characterization of lipid-containing marine bacteriophage PM2 by transposon insertion mutagenesis. J Virol. (2006) 80:9270ā8. doi: 10.1128/JVI.00536-06
35.
MaYPacanJCWangQXuYHuangXKorenevskyAet al. Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. Appl Environ Microbiol. (2008) 74:4799ā805. doi: 10.1128/AEM.00246-08,
36.
GuanPWangYZhangTShaoYDingYWangJet al. Isolation, characterization and biocontrol potential of the novel lytic phage SCP6: inhibiting biofilm formation and eradicating Salmonella Choleraesuis in food systems. Food Biosci. (2026) 79:108818. doi: 10.1016/j.fbio.2026.108818
37.
KhanMSIWuJHouSJiSLiHChangYet al. Bile modulates phageāhost interactions in multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol. (2025) 25:666. doi: 10.1186/s12866-025-04379-5,
38.
WangT. Landscape phage fusion Protein-Modified Pharmaceutical Nanocarriers for Targeted and Cytoplasmic Delivery of Chemotherapeutics to Breast cancer cells in vitro and in vivo. Boston, MA, United States: Northeastern University (2012).
39.
GhotraBSVasanthanTWettasingheMGoelV. A rapid method to determine quantitatively the in vitro adsorption of taurocholate to soluble fiber. Cereal Foods World. (2006) 51:118. doi: 10.1094/cfw-51-0118
40.
SimaPVannucciLVetvickaV. β-Glucans and cholesterol. Int J Mol Med. (2018) 41:1799ā808. doi: 10.3892/ijmm.2018.3411,
41.
VeverkaMDubajTGalloviÄJVeverkovĆ”EÅ imonPLokajJet al. Formulations of Staphylococcus aureus bacteriophage in biodegradable beta-glucan and arabinogalactan-based matrices. J Drug Deliv Sci Technol. (2020) 59:101909. doi: 10.1016/j.jddst.2020.101909
42.
BarrJJAuroRSam-SoonNKassegneSPetersGBonillaNet al. Subdiffusive motion of bacteriophage in mucosal surfaces increases the frequency of bacterial encounters. Proc Natl Acad Sci. (2015) 112:13675ā80. doi: 10.1073/pnas.1508355112,
43.
BarrJJAuroRFurlanMWhitesonKLErbMLPoglianoJet al. Bacteriophage adhering to mucus provide a nonāhost-derived immunity. Proc Natl Acad Sci. (2013) 110:10771ā6. doi: 10.1073/pnas.1305923110,
44.
WuJFuKHouCWangYJiCXueFet al. Bacteriophage defends murine gut from Escherichia coli invasion via mucosal adherence. Nat Commun. (2024) 15:4764. doi: 10.1038/s41467-024-48560-2,
45.
MerrilCRBiswasBCarltonRJensenNCCreedGJZulloSet al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci. (1996) 93:3188ā92. doi: 10.1073/pnas.93.8.3188,
46.
DÄ browskaK. Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev. (2019) 39:2000ā25. doi: 10.1002/med.21572,
47.
TanXChenKJiangZLiuZWangSYingYet al. Evaluation of the impact of repeated intravenous phage doses on mammalian hostāphage interactions. J Virol. (2024) 98:e0135923. doi: 10.1128/jvi.01359-23,
48.
RastogiSGangwarMSinghSKShuklaASinghDRastogiVet al. Preclinical evaluation of route-dependent immune responses following repeated administration of a Klebsiella pneumoniae lytic phage cocktail in rats. Mol Biol Rep. (2026) 53:1135. doi: 10.1007/s11033-026-12330-8,
49.
ShamsuzzamanMDChoiYJKimSJeongJYAm HongCKimJ. PEGylation overcomes pharmacological barriers to improve systemic pharmacokinetics and therapeutic efficacy of phages against MDR Escherichia coli. J Microbiol Biotechnol. (2025) 35. doi: 10.4014/jmb.2509.09050
50.
VinnerGKRichardsKLeppanenMSagonaAPMalikDJ. Microencapsulation of enteric bacteriophages in a pH-responsive solid oral dosage formulation using a scalable membrane emulsification process. Pharmaceutics. (2019) 11:475. doi: 10.3390/pharmaceutics11090475,
51.
ManoharPRameshN. Improved lyophilization conditions for long-term storage of bacteriophages. Sci Rep. (2019) 9:15242. doi: 10.1038/s41598-019-51742-4,
52.
PuapermpoonsiriUSpencerJvan der WalleCF. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm. (2009) 72:26ā33. doi: 10.1016/j.ejpb.2008.12.001,
53.
LeiboSPMazurP. Effect of osmotic shock and low salt concentration on survival and density of bacteriophages T4B and T4Bo1. Biophys J. (1966) 6:747ā72. doi: 10.1016/S0006-3495(66)86693-6,
54.
ZhaiXCastro-MejĆaJLGobbiAAslampaloglouAKotWNielsenDSet al. The impact of storage buffer and storage conditions on fecal samples for bacteriophage infectivity and metavirome analyses. Microbiome. (2023) 11:193. doi: 10.1186/s40168-023-01632-9,
55.
XuZDingZZhangYLiuXWangQShaoSet al. Shelf-life prediction and storage stability of Aeromonas bacteriophage vB_AsM_ZHF. Virus Res. (2023) 323:198997. doi: 10.1016/j.virusres.2022.198997,
56.
KimEJLimMCWooMAKimBSLimJA. Development of stabilizing solution for long-term storage of bacteriophages at room temperature and application to control foodborne pathogens. Viruses. (2024) 16:1155. doi: 10.3390/v16071155,
57.
AlmekhlafiSAFarragMAAl-WahibiMSAl-RashedSAlmaarikBMMarraikiNA. Encapsulation of bacteriophages in alginate beads: improved viability under harsh simulated gastric and intestinal conditions for phage therapy applications. Pharmaceuticals (Basel). (2026) 19:363. doi: 10.3390/ph19030363,
58.
SchubertCFischerSDorschKTeĆmerLHinrichsJAtamerZ. Microencapsulation of bacteriophages for the delivery to and modulation of the human gut microbiota through milk and cereal products. Appl Sci (Basel). (2022) 12:6299. doi: 10.3390/app12136299
59.
VerthĆ©KPossemiersSBoonNVaneechoutteMVerstraeteW. Stability and activity of an Enterobacter aerogenes-specific bacteriophage under simulated gastro-intestinal conditions. Appl Microbiol Biotechnol. (2004) 65:465ā72. doi: 10.1007/s00253-004-1585-7,
60.
SmithHWHugginsMBShawKM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. Microbiology. (1987) 133:1111ā26. doi: 10.1099/00221287-133-5-1111,
61.
ZhangYSotoMGhoshDWilliamsROIII. Manufacturing stable bacteriophage powders by including buffer system in formulations and using thin film freeze-drying technology. Pharm Res. (2021) 38:1793ā804. doi: 10.1007/s11095-021-03111-y,
62.
WangXXieZZhaoJZhuZYangCLiuY. Prospects of inhaled phage therapy for combatting pulmonary infections. Front Cell Infect Microbiol. (2021) 11:758392. doi: 10.3389/fcimb.2021.758392,
63.
KubalaA. Development and Evaluation of novel Methods to Improve phage-based Detection Methods. Nottingham, United Kingdom: University of Nottingham (2023).
64.
KhanSIlyasNSyedHAZafarSNawazH. Recent strategies for the formulation, stabilization, and delivery of bacteriophages to various infectious sites. Abasyn J Life Sci. (2025) 8:51ā64. doi: 10.5281/zenodo.15711191
65.
RotmanSGSumrallEZiadlouRGrijpmaDWRichardsRGEglinDet al. Local bacteriophage delivery for treatment and prevention of bacterial infections. Front Microbiol. (2020) 11:538060. doi: 10.3389/fmicb.2020.538060,
66.
TangZHuangXSabourPMChambersJRWangQ. Preparation and characterization of dry powder bacteriophage K for intestinal delivery through oral administration. LWT Food Sci Technol. (2015) 60:263ā70. doi: 10.1016/j.lwt.2014.08.012
67.
KimSGGiriSSJoSJKangJWLeeSBJungWJet al. Prolongation of fate of bacteriophages in vivo by polylactic-co-glycolic-acid/alginate-composite encapsulation. Antibiotics. (2022) 11:1264. doi: 10.3390/antibiotics11091264,
68.
AbdelsattarASAbdelrahmanFDawoudAConnertonIFEl-ShibinyA. Encapsulation of E. coli phage ZCEC5 in chitosanāalginate beads as a delivery system in phage therapy. AMB Express. (2019) 9:87. doi: 10.1186/s13568-019-0810-9,
69.
YueYXuZSoteyomeTPremarathnaMYinXLiuJ. Phage encapsulation and delivery technology: a strategy for treating drug-resistant pathogenic microorganisms. Pharmaceuticals. (2025) 18:1688. doi: 10.3390/ph18111688,
70.
TabareEDauchotTCochezCGlontiTAntoineCLaforĆŖtFet al. EudragitĀ® FS microparticles containing bacteriophages, prepared by spray-drying for oral administration. Pharmaceutics. (2023) 15:1602. doi: 10.3390/pharmaceutics15061602,
71.
TabareEGlontiTCochezCNgassamCPirnayJPAmighiKet al. A design of experiment approach to optimize spray-dried powders containing Pseudomonas aeruginosa podoviridae and myoviridae bacteriophages. Viruses. (2021) 13:1926. doi: 10.3390/v13101926,
72.
Acar SoykutETayyarcanEKEvranÅBoyacıİHĆakırİKhaaladiMet al. Microencapsulation of phages to analyze their demeanor in physiological conditions. Folia Microbiol. (2019) 64:751ā63. doi: 10.1007/s12223-019-00688-1,
73.
SuboorA. Development and Optimization of a Feasible Drying Formulation for phage-Carrier Biopesticide against fire Blight. Guelph, Ontario, Canada: University of Guelph (2024).
74.
SharmaPVashisthMJaglanABGuptaJKapoorPBhutaniKet al. Nanotechnologies for targeted bacteriophage therapy: a review. Environ Chem Lett. (2026) 24:139ā72. doi: 10.1007/s10311-025-01881-0
75.
Pardo-FreireMDomingo-CalapP. Phages and nanotechnology: new insights against multidrug-resistant bacteria. Biodes Res. (2023) 5:0004. doi: 10.34133/bdr.0004,
76.
SinglaSHarjaiKKatareOPChhibberS. Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS One. (2016) 11:e0153777. doi: 10.1371/journal.pone.0153777,
77.
ChhibberSShuklaAKaurS. Transfersomal phage cocktail is an effective treatment against methicillin-resistant Staphylococcus aureus-mediated skin and soft tissue infections. Antimicrob Agents Chemother. (2017) 61:e02146ā16. doi: 10.1128/AAC.02146-16,
78.
BalkrishnaAKumarAKumariAAryaVThakurNJeetKet al. Phage-antibiotics synergy and nanotechnology interventions in the management of drug resistance among bacterial pathogens: a scoping review. Int J Pharm. (2025) 686:126299. doi: 10.1016/j.ijpharm.2025.126299,
79.
KaurSKumariAKumari NegiAGalavVThakurSAgrawalMet al. Nanotechnology based approaches in phage therapy: overcoming the pharmacological barriers. Front Pharmacol. (2021) 12:699054. doi: 10.3389/fphar.2021.699054,
80.
MukhopadhyaySToKKLiuYBaiCLeungSS. A thermosensitive hydrogel formulation of phage and colistin combination for the management of multidrug-resistant Acinetobacter baumannii wound infections. Biomater Sci. (2023) 12:151ā63. doi: 10.1039/D3BM01383A,
81.
YangYLiRZhongQGuoYWuRChenHet al. In situ gut microbiota editing: enhancing therapeutic efficacy for bacterial colitis by compatible oral hydrogel microspheres with phages. Nat Commun. (2025) 16:9785. doi: 10.1038/s41467-025-65498-1,
82.
VacekLKleknerovĆ”DPLipovýBHoloubekJMatyskovĆ”DÄernĆ”Eet al. Phage therapy combined with gum Karaya injectable hydrogels for treatment of methicillin-resistant Staphylococcus aureus deep wound infection in a porcine model. Int J Pharm. (2024) 660:124348. doi: 10.1016/j.ijpharm.2024.124348,
83.
NarayananKBBhaskarRChoiSMHanSS. Development of carrageenan-immobilized lytic coliphage vB_Eco2571-YU1 hydrogel for topical delivery of bacteriophages in wound dressing applications. Int J Biol Macromol. (2024) 259:129349. doi: 10.1016/j.ijbiomac.2024.129349,
84.
PirnayJPDjebaraSSteursGGriselainJCochezCDe SoirSet al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. (2024) 9:1434ā53. doi: 10.1038/s41564-024-01705-x,
85.
Loc-CarrilloCAbedonST. Pros and cons of phage therapy. Bacteriophage. (2011) 1:111ā4. doi: 10.4161/bact.1.2.14590,
86.
FujimotoK. Metagenome data-based phage therapy for intestinal bacteria-mediated diseases. Biosci Microbiota Food Health. (2023) 42:8ā12. doi: 10.12938/bmfh.2022-061,
87.
Van BelleghemJDMerabishviliMVergauwenBLavigneRVaneechoutteM. A comparative study of different strategies for removal of endotoxins from bacteriophage preparations. J Microbiol Methods. (2017) 132:153ā9. doi: 10.1016/j.mimet.2016.11.020,
88.
BranstonSDWrightJKeshavarz-MooreE. A non-chromatographic method for the removal of endotoxins from bacteriophages. Biotechnol Bioeng. (2015) 112:1714ā9. doi: 10.1002/bit.25571,
89.
PeezCChenBHensslerLChittòMOnseaJVerhofstadMHet al. Evaluating the safety, pharmacokinetics and efficacy of phage therapy in treating fracture-related infections with multidrug-resistant Staphylococcus aureus: intravenous versus local application in sheep. Front Cell Infect Microbiol. (2025) 15:1547250. doi: 10.3389/fcimb.2025.1547250,
90.
WannigamaDLShaoJSunHWangYHurstCMonkPNet al. Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections. Arch Microbiol. (2025) 207:310. doi: 10.1007/s00203-025-04526-6,
91.
Torres-BoncompteJGarcia-LlorensJCortĆ©sPMartĆnez-SĆ”nchezALlagosteraMCampoySet al. In ovo phage administration to mitigate Salmonella Typhimurium colonization in broiler chickensāa new firewall strategy for the poultry industry. Food Control. (2025) 180:111637. doi: 10.1016/j.foodcont.2025.111637
92.
CheethamBFWhittleGTingMKatzME. Interactions between bacteriophage DinoHI and a network of integrated elements which control virulence in Dichelobacter nodosus, the causative agent of ovine footrot. In: Witzany G, editor. Biocommunication in Soil Microorganisms. Berlin, Heidelberg: Springer Berlin Heidelberg (2010). p. 237ā53.
93.
KrƶmkerVLeimbachSTellenAWenteNSchmidtJLehnherrHet al. Randomized, negative-controlled pilot study on the treatment of intramammary Staphylococcus aureus infections in dairy cows with a bacteriophage cocktail. Antibiotics. (2026) 15:32. doi: 10.3390/antibiotics15010032,
94.
TitzeIKrƶmkerV. Antimicrobial activity of a phage mixture and a lactic acid bacterium against Staphylococcus aureus from bovine mastitis. Vet Sci. (2020) 7:31. doi: 10.3390/vetsci7010031,
95.
da Silva DuarteVDiasRSKropinskiAMCampanaroSTreuLSiqueiraCet al. Genomic analysis and immune response in a murine mastitis model of vB_EcoM-UFV13, a potential biocontrol agent for use in dairy cows. Sci Rep. (2018) 8:6845. doi: 10.1038/s41598-018-24896-w,
96.
PillayC. Biological Characterization of South African Bacteriophages Infective against Streptococcus uberis, a Causal agent of Bovine Mastitis. Pietermaritzburg: University of KwaZulu-Natal (2019).
97.
Vander ElstNBertJFavoreelHLavigneRMeyerEBriersY. Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens. Microb Biotechnol. (2023) 16:2367ā86. doi: 10.1111/1751-7915.14339,
98.
CaoYWangYLiMKhanalDChanHK. Can bacteriophage be stabilised by lipid encapsulation when nebulised for inhalation delivery against Pseudomonas aeruginosa?Int J Pharm. (2025) 678:125670. doi: 10.1016/j.ijpharm.2025.125670,
99.
AstudilloALeungSSYKutterEMoralesSChanHK. Nebulization effects on structural stability of bacteriophage PEV 44. Eur J Pharm Biopharm. (2018) 125:124ā30. doi: 10.1016/j.ejpb.2018.01.010,
100.
ThompsonDL. Evaluating Nebulizer Efficiency for phage Therapy in Drug-Resistant Pseudomonas Infections. New Haven, CT, United States: Yale University (2025).
101.
YanWHeRTangXTianBLiuYTongYet al. The influence of formulation components and environmental humidity on spray-dried phage powders for treatment of respiratory infections caused by Acinetobacter baumannii. Pharmaceutics. (2021) 13:1162. doi: 10.3390/pharmaceutics13081162,
102.
HuffWEHuffGRRathNCBalogJMDonoghueAM. Prevention of Escherichia coli infection in broiler chickens with a bacteriophage aerosol spray. Poult Sci. (2002) 81:1486ā91. doi: 10.1093/ps/81.10.1486,
103.
HuffWEHuffGRRathNCBalogJMDonoghueAM. Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult Sci. (2003) 82:1108ā12. doi: 10.1093/ps/82.7.1108,
104.
BasselLLKaufmanEIAlsopSNAStinsonKJHewsonJSharifSet al. Development of an aerosolized Mannheimia haemolytica experimental pneumonia model in clean-catch colostrum-deprived calves. Vet Microbiol. (2019) 234:34ā43. doi: 10.1016/j.vetmic.2019.05.012,
105.
AntoineCMackayDMidtlyngPKleppenHPPaliÄDPirnayJPet al. Bacteriophage-based veterinary products: aligning regulatory framework and development challenges for market integration. Biologicals. (2025) 91:101847. doi: 10.1016/j.biologicals.2025.101847,
106.
CuteriVStoroniCCaoSLiY. Artificial intelligence-driven phage therapy in veterinary medicine: an adaptive one health strategy to mitigate antimicrobial resistance in livestock systems. Front Vet Sci. (2026) 13:1829777. doi: 10.3389/fvets.2026.1829777,
107.
ShahdadiMSafariradMBeriziEHosseinzadehSPhimolsiripolYKhaneghahAM. Investigating the effect of phage on reducing Salmonella spp. in poultry meat: a systematic review and meta-analysis. Food Control. (2024) 160:110380. doi: 10.1016/j.foodcont.2024.110380
108.
TidimGGuzelMSoyerYErel-GoktepeI. Layer-by-layer assembly of chitosan/alginate thin films containing Salmonella enterica bacteriophages for antibacterial applications. Carbohydr Polym. (2024) 328:121710. doi: 10.1016/j.carbpol.2023.121710,
109.
PrachoochoteSJanesomboonSPhothawornPWithatanungPNaleJYGalyovEEet al. Alginate encapsulation enhanced the gastrointestinal stability and bactericidal efficacy of an optimized Salmonella phage cocktail for oral delivery in poultry feed. Poult Sci. (2025) 105:106272. doi: 10.1016/j.psj.2025.106272,
110.
WagenaarJAVan BergenMAMuellerMAWassenaarTMCarltonRM. Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet Microbiol. (2005) 109:275ā83. doi: 10.1016/j.vetmic.2005.06.002,
111.
PehESzottVReicheltBFrieseARƶslerUPlƶtzMet al. Bacteriophage cocktail application for Campylobacter mitigationāfrom in vitro to in vivo. BMC Microbiol. (2023) 23:209. doi: 10.1186/s12866-023-02963-1,
112.
ScottAETimmsARConnertonPLEl-ShibinyAConnertonIF. Bacteriophage influence Campylobacter jejuni types populating broiler chickens. Environ Microbiol. (2007) 9:2341ā53. doi: 10.1111/j.1462-2920.2007.01351.x,
113.
ScottAETimmsARConnertonPLLoc CarrilloCAdzfa RadzumKConnertonIF. Genome dynamics of Campylobacter jejuni in response to bacteriophage predation. PLoS Pathog. (2007) 3:e119. doi: 10.1371/journal.ppat.0030119,
114.
TolojanaharyTOXuMLiuSYangC. The efficacy of bacteriophage therapy in reducing pathogen load in challenged piglets: a meta-analysis. Anim Nutriomics. (2026) 3:1ā30. doi: 10.1017/anr.2026.10045
115.
ChenJHanJYangZZhouWHeYChenXet al. Bacteriophages as potential anti-pathogenic agents for intestinal health of weaned piglets in the post-antibiotic era: an updated review. Animals. (2025) 15:1713. doi: 10.3390/ani15121713,
116.
DlaminiSBGiganteAMHootonSPAtterburyRJ. Efficacy of different encapsulation techniques on the viability and stability of diverse phage under simulated gastric conditions. Microorganisms. (2023) 11:2389. doi: 10.3390/microorganisms11102389,
117.
ZhangJKraftBLPanYWallSKSaezACEbnerPD. Development of an anti-Salmonella phage cocktail with increased host range. Foodborne Pathog Dis. (2010) 7:1415ā9. doi: 10.1089/fpd.2010.0621,
118.
ImklinNSriprasongPPhuttapatimokSKaminsonsakulTWoonwongYJirawattanapongPet al. In vivo assessment of bacteriophages specific to multidrug resistant Escherichia coli on fecal bacterial counts and microbiome in nursery pigs. Res Vet Sci. (2022) 151:138ā48. doi: 10.1016/j.rvsc.2022.07.012,
119.
PiyaDLessorLKoehlerBStonecipherACahillJGillJJ. Genome-wide screens reveal Escherichia coli genes required for growth of T1-like phage LL5 and V5-like phage LL12. Sci Rep. (2020) 10:8058. doi: 10.1038/s41598-020-64981-7,
120.
BachSJCookSRWangYStanfordKJohnsonRMcAllisterTA. Escherichia coli O157 bacteriophages: lytic activity and effects on fermentation in ruminal batch culture. Can J Anim Sci. (2012) 92:545ā50. doi: 10.4141/cjas2012-084
121.
RivasLCoffeyBMcAuliffeOMcDonnellMJBurgessCMCoffeyAet al. In vivo and ex vivo evaluations of bacteriophages e11/2 and e4/1c for use in the control of Escherichia coli O157. Appl Environ Microbiol. (2010) 76:7210ā6. doi: 10.1128/AEM.01530-10
122.
RotmanSGPostVFosterALLavigneRWagemansJTrampuzAet al. Alginate chitosan microbeads and thermos-responsive hyaluronic acid hydrogel for phage delivery. J Drug Deliv Sci Technol. (2023) 79:103991. doi: 10.1016/j.jddst.2022.103991,
123.
GautamVKWalwadkarKNathGSinghAPShrivastavaNBanerjeeS. Therapeutic efficacy of bacteriophage and antibiotics in staphylococcal mastitis in cattle. Genet Mol Res. (2026). doi: 10.4238/v5tc0x28
124.
TitzeILehnherrTLehnherrHKrƶmkerV. Efficacy of bacteriophages against Staphylococcus aureus isolates from bovine mastitis. Pharmaceuticals. (2020) 13:35. doi: 10.3390/ph13030035,
125.
SchmoellerEde MatosADRahalNMFeijoJOBraunerCCDel PinoFABet al. Diarrhea duration and performance outcomes of pre-weaned dairy calves supplemented with bacteriophage. Can J Anim Sci. (2021) 102:165ā74. doi: 10.1139/cjas-2021-0074
126.
PhageLab. MSD animal health launches PHAGEIN in Brazil: technology developed by PhageLab to combat neonatal calf diarrhea. (2025). Available online at: https://phage-lab.com/2025/05/16/msd-animal-health-launches-phagein-in-brazil-technology-developed-by-phagelab-to-combat-neonatal-calf-diarrhea/ (Accessed July 15, 2026).
127.
MoqaddesS.In vitro evaluation and in vivo assessment of bacteriophage endolysins and antimicrobial peptides against Mannheimia Haemolytica and Pasteurella multocida associated with bovine respiratory disease. (2026). Available online at: https://hdl.handle.net/1880/125416 (Accessed July 17, 2026).
128.
Urban-ChmielRNowaczekAChmielPWawrzykowskiJPyzikEMarekAet al. Determination of anti-phage antibodies in calf sera following application of Escherichia coli and Mannheimia haemolytica-specific bacteriophages. J Vet Res. (2022) 66:353ā60. doi: 10.2478/jvetres-2022-0041,
129.
NgocLHBAnhNTLAnhVNTUyenNTPDungLVVanTTB. Infectious characteristics of some Vibrio spp. phages isolated in shrimp farming of the Mekong delta. J Appl Biol Biotechnol. (2024) 12:48ā54. doi: 10.7324/jabb.2024.154284
130.
Le RouxF. The ecology and evolution of microbial immune systems: a look on the wild Vibrio side. Philos Trans R Soc B Biol Sci. (2025) 380:20240078. doi: 10.1098/rstb.2024.0078,
131.
BernardCLabreucheYDiarraCDaszkowskiPCahierKGoudenĆØgeDet al. Generalists in a specialist world: Vibrio-phages with broad host range. bioRxiv. (2024) 2024:12. doi: 10.1101/2024.12.24.630238
132.
DengZZengSZhouRHouDBaoSZhangLet al. Phage-prokaryote coexistence strategy mediates microbial community diversity in the intestine and sediment microhabitats of shrimp culture pond ecosystem. Front Microbiol. (2022) 13:1011342. doi: 10.3389/fmicb.2022.1011342,
133.
CahierKPielDBarcia-CruzRGoudenĆØgeDWegnerKMMonotMet al. Environmental Vibrio phageābacteria interaction networks reflect the genetic structure of host populations. Environ Microbiol. (2023) 25:1424ā38. doi: 10.1111/1462-2920.16366,
134.
PradhanSKDeviRKhanMIRKamilyaDChoudhuryTGParhiJ. Isolation of Aeromonas salmonicida subspecies salmonicida from aquaculture environment in India: polyphasic identification, virulence characterization, and antibiotic susceptibility. Microb Pathog. (2023) 179:106100. doi: 10.1016/j.micpath.2023.106100,
135.
International Alliance for Biological Standardization (IABS) Avoiding antimicrobial resistance: veterinary use of phages for prevention, therapy and control of bacterial infections. (2024). Available online at: https://events.iabs.org/phages-virtualmeeting-2024
136.
HussainSKhanSKhanRKhanAGamaryaniAMohsinMet al. Innovations in poultry disease control: advancements in bacteriophage therapy and delivery systems. Pak Vet J. (2025) 45:993ā1000. doi: 10.29261/pakvetj/2025.213
137.
ShakirMZRizviFMasoudFRafiqueAUsmaniMWNaseemMNet al. Seroprevalence, molecular confirmation and application of bacteriophage as a potential prophylactic therapy against fowl typhoid disease in commercial poultry birds. Pak Vet J. (2024) 44:1185ā92. doi: 10.29261/pakvetj/2024.302,
138.
SarmykovaMYespembetovBSambetbayevATileukhanovKKaldyrkaevAShestakovAet al. Isolation and characterization of bacteriophage Streptococcus equi for application against horse strangles. Int J Vet Sci. (2024) 13:691ā9. doi: 10.47278/journal.ijvs/2024.155
139.
Torres-BarcelóCTurnerPEBucklingA. Mitigation of evolved bacterial resistance to phage therapy. Curr Opin Virol. (2022) 53:101201. doi: 10.1016/j.coviro.2022.101201,
140.
AhnEKimJTobinIShinDHaEZhangGet al. Cross-resistance-guided phage cocktail design for effective mitigation of necrotic enteritis in poultry. Microbiol Res. (2026) 307:128473. doi: 10.1016/j.micres.2026.128473,
141.
FujikiJYamadaAShinzatoRHiyaRNorihisaNImaiKet al. Immuno-phage synergy driven by fitness costs: turning bacterial phage resistance into therapeutic gain through evolutionary traps. Front Immunol. (2026) 17:1856088. doi: 10.3389/fimmu.2026.1856088,
142.
KinantiASPrihantoAAJatmikoYDKobunRFeliciaWXL. Harnessing bacteriophages: a promising approach to combat foodborne pathogen biofilms. Int J Agric Biosci. (2024) 13:656ā68. doi: 10.47278/journal.ijab/2024.172
143.
HerrenSCZinkCLMandrekarJPatelR. Precision of a phage susceptibility spot assay assessed with 154 clinical Staphylococcus aureus isolates. Microbiol Spectrum. (2026) 14:e03284ā25. doi: 10.1128/spectrum.03284-25,
144.
Mora-QuilisLSanjuƔnRDomingo-CalapP. Phenotypic heterogeneity shapes phage resistance and cocktail efficacy in Klebsiella pneumoniae. Microbiol Spectrum. (2026) 14:e0226125. doi: 10.1128/spectrum.02261-25,
145.
ChadhaPKatareOPChhibberS. Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns. (2017) 43:1532ā43. doi: 10.1016/j.burns.2017.03.029,
146.
YangYShiCWangHKeLWangHZhouM. Biological control evaluation of bacteriophage freeze-dried powder against Aeromonas hydrophila infection, based on whey protein/trehalose. Microb Pathog. (2026) 218:108675. doi: 10.1016/j.micpath.2026.108675
147.
ChangRYWongJMathaiAMoralesSKutterEBrittonWet al. Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. Eur J Pharm Biopharm. (2017) 121:1ā13. doi: 10.1016/j.ejpb.2017.09.002,
148.
ChengAFYChoiDTCLiuYBaiCLeungSSY. Storage stability prediction of spray dried anti-Acinetobacter baumannii phage and phage cocktail powders. Int J Pharm. (2025) 681:125842. doi: 10.1016/j.ijpharm.2025.125842,
149.
MatinkhooSLynchKHDennisJJFinlayWHVehringR. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J Pharm Sci. (2011) 100:5197ā205. doi: 10.1002/jps.22715,
150.
AbdelrahmanFMakkySTebaHEAgwaMMAbd ElazizMMAwadRet al. Potential of vB_Pa_ZCPS1 phage embedded in situ gelling formulations as an ocular delivery system to attenuate Pseudomonas aeruginosa keratitis in a rabbit model. J Control Release. (2025) 380:52ā70. doi: 10.1016/j.jconrel.2025.01.091,
151.
KwonJKimSGKimSWKimHJKangJWJoSJet al. Tailoring formulation for enhanced phage therapy in canine otitis externa: a cocktail approach targeting Pseudomonas aeruginosa and Staphylococcus pseudintermedius. Vet Microbiol. (2025) 301:110354. doi: 10.1016/j.vetmic.2024.110354,
152.
WasamMZSheikhAAAnjumAABeigMMFiryalSKokabAet al. Efficacy of a bacteriophage cocktail in controlling Salmonella Enteritidis infection in broiler chickens. Iran J Microbiol. (2026) 18:338. doi: 10.18502/ijm.v18i3.21658
153.
MahmudMRUddinMKKareljƤrviPJalasvuoriMPerƤkylƤJEklundTet al. Impact of phage therapy in post-weaning piglets challenged with ETEC strain in a controlled minitrial. Porcine Health Manag. (2026) 12:36. doi: 10.1186/s40813-026-00516-2,
154.
NickodemCAArnoldANBeckMRBushKJGehringKBGillJJet al. An experimental field trial investigating the use of bacteriophage and manure slurry applications in beef cattle feedlot pens for Salmonella mitigation. Animals. (2023) 13:3170. doi: 10.3390/ani13203170,
155.
DingHShiKHsiaoMLiWLiuXXuJet al. Two virulent Vibrio campbellii phages with potential for phage therapy in aquaculture. BMC Microbiol. (2025) 25:99. doi: 10.1186/s12866-025-03803-0,
Summary
Keywords
antimicrobial resistance, bacteriophage cocktails, formulation strategies, livestock, physicochemical barriers, treatment outcome, veterinary phage therapy
Citation
Muneeb M, Tharwat M, Shaukat A, Nassar N, Qu Y, Khan AY and Alshanbari FA (2026) Formulation, stability, and delivery of bacteriophage cocktails in veterinary medicine: a review of physicochemical constraints and therapeutic outcomes in production animals. Front. Vet. Sci. 13:1988130. doi: 10.3389/fvets.2026.1988130
Received
04 September 2026
Revised
07 October 2026
Accepted
07 October 2026
Published
15 October 2026
Volume
13 - 2026
Edited by
Shana Coelho, Federal Rural University of Rio de Janeiro, Brazil
Reviewed by
Mateusz Wdowiak, University of Warsaw, Poland
Manju Bernela, National Research Centre on Equines (ICAR), India
Updates
Copyright
Ā© 2026 Muneeb, Tharwat, Shaukat, Nassar, Qu, Khan and Alshanbari.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yonggang Qu, quyonggang@shzu.edu.cn; Fahad A. Alshanbari, shnbry@qu.edu.sa
ā These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.